Abstract
The value of anabolic steroids (AST) in the treatment of several more or less well-defined indications has been described in other sections of this book. The aim of the present chapter is to list, discuss, and where possible evaluate the remaining available data on the therapeutic use of these preparations.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Adám, G., Miltényi, L., Dézsi, Z., Jóna, G.: Die Wirkung von Nandrolone-Dekanoat auf den Eisenumsatz des Organismus nach Bestrahlung. Strahlentherapie 136, 113–115 (1968).
Adám, G., Miltényi, L., Molnár, A.: Die Wirkung von Nandrolon-Dekanoat und Eisenpräparaten auf das Blutbild von bestrahlten Patienten. Strahlentherapie 141, 696–698 (1971).
Adda, M.: Etude sur 50 malades immobilisés traités par le stromba pendant deux ans. Sem. Hôp. Paris 75–76 (1965).
Aepli, R.: Potentialisation de l’action anti-inflammatoire des corticosteroides par le Dianabol dans le traitement au long cours de l’asthme bronchique. Schweiz. med. Wschr. 94, 53–57 (1964).
Agapova, E.N., Tkachenko, A.M., Krutovskaya, O.V.: Use of anabolic preparations in atherosclerotic cardiosclerosis. Klin. Med. (Moskau) 52, 42–44 (1974).
Ahlendorf, W., Kob, D.: Stationäre Nachbehandlung von Patienten mit reseziertem Magenkarzinom. Arch. Geschwulstforsch. 36, 64–75 (1970).
Ahrends, H.: Beitrag zum familiären Vorkommen und zur Therapie der Cystinose. Z. Kinder-heilk. 99, 101 (1967).
Akzhigitov, G.N., Usatova, I.Y., Kaplan, L.D.: Use of glucocorticoid and anabolic hormones in the treatment of acute pancreatitis. Terap. Arkh. 43, 52–57 (1971).
Albanese, A.A.: Newer methodology in the clinical investigation of anabolic steroids. J. new Drugs 5, 208–224 (1965).
Albanese, A.A., Lorenze, E.J., Orto, L.A., Smullyan, J.L.: Nutritional and metabolic effects of some newer steroids. N.Y. St. J. Med. 65, 2116–2125 (1965).
Albanese, A.A., Woodhull, M.L., Orto, L.A., Zavattaro, D.N., Wein, E.H.: Steroid and dietary effects on blood lipids in elderly persons. Nutr. Rep. Intern. 1, 231–242 (1970).
Alberto, S., Colongo, P., Brusasco, L.: Comments on the anti-asthenic and anti-depressive properties of androstanazol in geriatrics. Minerva med. 59, 2288–2293 (1968).
Al-Hussaini, M., McGillis, A., Frank, I.N., McDonals, D.F.: Anabolic effect of norethandro-lone and nandrolone phenpropionate in uremic rats. Invest. Urol. 3, 537–545 (1965).
Allenby, F., Jeyasingh, K., Calnan, J.: Ethyloestrenol and postoperative venous thrombosis. Lancet 1973II, 38–39.
Almér, L.-O., Pandolfi, M., Nilsson, I.M.: Diabetic retinopathy and the fibrinolytic system. Diabetes 24, 529–534 (1975).
Aly, F.W.: Klinische Erfahrungen mit einem nichtvirilisierenden, oral wirksamen Testosteron-Derivat (Dehydro-17-Methyltestosteron). Med. Welt 47, 2468–2473, Part 1 (1961)
Aly, F.W.: Klinische Erfahrungen mit einem nichtvirilisierenden, oral wirksamen Testosteron-Derivat (Dehydro-17-Methyltestosteron). Med. Welt 48, 2513–2520, Part 2 (1961).
Ambrus, C.M., Ambrus, J.L.: Myeloid regeneration after whole body irradiation, autologous bone marrow transplantation, and treatment with an anabolic steroid. J. Med. Exp. Clin. 6, 27–32 (1975).
Ambrus, J.L., Mirand, E.A.: Effect of autologous bone marrow transplantation and an anabolic steroid on erythropoietin production and hemopoietic recovery after whole body irradiation and treatment with alkylating agents. J. Med. 4, 65–81 (1973).
Ammedick, U., Konrad, R.M., Gotzen, E.: Über die Wirksamkeit anaboler Steroide in der postoperativen Phase. Med. Ernähr. 9, 121–123 (1968).
Antonini, F.M., Verdi, G.: Investigations concerning a new anabolic synthetic steroid: oxy-metholone. Behaviour of some lipid fractions of the serum. G. Geront. 9, 1051–1065 (1961).
Ariel, G., Saville, W.: The effect of anabolic steroids on reflex components. Med. Sci. Sports 4, 120–123 (1972).
Arthur, K.: Some aspects of chemotherapy in breast carcinomatosis. Clin. Radiol. 19, 351–356 (1968).
Babel, J.: Le traitement de la rétinopathie diabétique par les anabolisants. Méd. et Hyg. 23, 485–486 (1965).
Badalyn, L.O., Dunaevskaya, G.N., Sitnikov, V.T.: Treatment of progressive muscular dystrophy. Zh. Nevropatol. Psikhiatr. 75, 1317–1323 (1975).
Bär, W., Usbeck, W.: Zur oralen Anwendung anaboler Hormone bei magenlosen Patienten. Dtsch. Gesundh.-Wes. 26, 1007–1009 (1971).
Bär, W., Usbeck, W.: Orale Anabolikatherapie bei magenlosen Patienten. Zbl. Chir. 99, 1306–1311 (1974).
Baker, C.D., Baum, G.: Use of an anabolic drug in malnutrition in the aged. Practitioner 193, 683–685 (1964).
Balakhovsky, I.S., Okhotsky, V.P., Fedorov, J.V., Doronin, E.I., Yakovleva, I.P.: Indications and applications of an anabolic steroid preparation in clinical orthopaedics. Klin. Med. (Moskau) 50, 110–114 (1972).
Balmes, A., Dauverchain, J., Othoniel, J., Juanchich, J.: Intérêt du Durabolin (phenylpropio-nate de 19-norandrosténolone) dans le traitement des pneumopathies aigues. Vie méd. 29, 3527–3536 (1969).
Barnes, H.D., Overton, J., Sweet, R.D.: Familial cutaneous porphyria. Brit. J. Derm. 77, 130–136 (1965).
Barwick, D.D., Newell, D.J., Walton, J.N.: Methandrostenolone and nandrolone decanoate in muscular dystrophy. A controlled trial. Neurology 13, 12–23 (1963).
Bauer, A., Krammer, H.: Erfahrungen mit Stromba in der Geriatrie. Ther. Umsch. 21, 194–207 (1964).
Bauer, B., Antener, I.: Eine wirksame diätetische und medikamentöse Cystinosebehandlung. Helv. paediat. Acta 21, 19–50 (1966).
Beaumont, J.-L., Carlson, L.A., Cooper, G., Fejfar, Z., Fredrickson, D.S., Strasser, T.: Classification of hyperlipidaemias and hyperlipoproteinaemias. Bull. Wld. Hlth. Org. 43, 891 (1970).
Beaumont, P., Hollows, F.G.: Classification of diabetic retinopathy, with therapeutic implications. Lancet 1972II, 419–424.
Becker, J., Kärcher, K.H., Kleibel, F.: Die zusätzliche Behandlung und Verlaufsbeobachtung während der Strahlentherapie und cytostatischen Behandlung. Radiologe 6, 159–175 (1966).
Beckmann, R.: Erfahrungen mit anabolen Steroiden bei Myopathien. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.
Beckmann, R.: Discussion on: Dowben, R.M., Anabole Steroide bei Myopathien. Myopathien. Stuttgart: Georg Thieme Verlag 1965.
Bei, P.I.: The use of nerobol in the treatment of patients with rheumatic heart defects and circulatory failure. Klin. Med. (Moskau) 46, 104–106 (1968).
Bei, P.I.: The effect of nerobol on the contractile capacity of the myocardium. Klin. Med. (Moskau) 50, 69–74 (1972).
Beiglböck, W., Brummund, W.: Über das Problem der anabolen Wirkung von Testosteron Derivaten (Bericht über Erfahrungen mit Dianabol). Med. Welt 22, 1192–1203 (1960).
Bekény, G., Kraft, F., Lang, S.: Die Anwendung von Durabolin (19-Nor-Androstenolon-phenylpropionat) in der Behandlung der Dystrophia musculorum progressiva. Nervenarzt 31, 118–123 (1960).
Benda, L., Geyer, G.: Untersuchungen über den Eiweiß-Stoffwechsel bei Leberkranken unter anabol wirksamen Steroiden. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.
Berger, H., Antener, J., Brechbühler, T., Stalder, G.: Zum Problem der Cystinose. Beobachtungen über den Cystinnachweis im Serum und therapeutische Erfahrungen mit Penicillamin und anabolem Hormon. Ann. Paediat. (Basel) 202, 465–482 (1964).
Bergmann, M.: Die Wirkung von „Deca-Durabolin” auf den Reststickstoffspiegel im Blut. Med. Welt 10, 538–543 (1962).
Berkowitz, D.: Anabolic agents in gastroenterology. Paper presented at a Symposium on Anabolic Therapy, Detroit, March 1962.
Berkowitz, D., Spitzer, J., Likoff, W.P.: Practical significance of serum triglycerides and radioactive fat tolerance: their relation to current therapy for hypercholesterolemia. Amer. J. Cardiol. 10, 198 (1962).
Besa, E.C., Gorshein, D., Gardner, F.H.: Androgens and human blood volume changes. Comparison in normal and various anemic states. Arch. intern. Med. 133, 418–425 (1974).
Bew, K.: A double-blind trial of an anabolic steroid in eighteen elderly women. Practitioner 194, 530–534 (1965).
Bielawiec, M., Perzanowski, A., Mysliwiec, M.: Long term therapy of patients suffering from occlusive arterial disease with combined therapy with phenformin and stanozolol. Throm-bos. Diathes. haemorrh. 34, 916–917 (1975).
Bielawski, W.: The effect of oxyterracin on rat liver cell in the course of gravidity and estradiol and durabolin treatment (2nd communication). Pol. Arch. Med. wewnet. 40, 15–20 (1968).
Bierich, J.R.: Erfahrungen mit Anabolika bei der progressiven Muskeldystrophie im Kindesalter. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.
Bierich, J.R., Grüttner, R., Landbeck, G.: Therapeutic effects of anabolic steroids in progressive muscular dystrophy. Paper at the 10th Internat. Congress of Pediatrics, Lisbon, 1962.
Blagg, C.R., Parsons, F.M.: Use of norethandrolone in acute renal failure from obstetric causes. Lancet 1960II, 577–581.
Blagg, C.R., Parsons, F.M.: Early dialysis and anabolic steroids in acute renal failure. Amer. Heart J. 61, 287–291 (1961).
Blair, A.J., Morgen, J.C., Beck, J.C.: The plasma 17-hydroxycorticosteroid levels in acute and chronic renal failure. Canad. J. Biochem. 39, 1617–1624 (1961).
Blahnikova, L.: A propos de l’indication des stéroides anabolisants dans le traitement des lésions hépatiques chroniques. Gastroenterologie 107, 354–359 (1967).
Blahnikova, L., Horky, J.: Einfluß der anabolen Steroide auf den Eiweißstoffwechsel bei verschiedener Proteinzufuhr bei chronisch Leberkranken. Z. Ernährungsw. Suppl. 13, 105–112 (1972).
Blasius, R., Käfer, K., Seitz, W.: Untersuchungen über die Wirkung von Testosteron auf die contractilen Strukturproteine des Herzens. Klin. Wschr. 34, 324–326 (1956).
Blasius, R., Käfer, K., Seitz, W.: Untersuchungen über die Abhängigkeit von androgener Wirkung und proteinaufbauendem Effekt der Steroid-Hormone auf die contractilen Muskelproteine des Herzens. Klin. Wschr. 35, 308–310 (1957).
Boillat, J.E., Saxena, B.M., Lehmann, H.E., Ban, T.A.: Combined administration of thioridazine, nicotinic acid and fluoxymesterone in the treatment of geriatric patients. Curr. ther. Res. 13, 541–544 (1971).
Bolch, O.H., Warren, J.C.: Induction of premature menstruation with catatoxic steroids. Amer. J. Obstet. Gynec. 111, 1107–1110 (1971).
Bond, W.H., Arthur, K.: Some observations on the use of cytotoxic drugs and anabolic steroids in the treatment of breast carcinomatosis. Paper read at a Symposium at the University Dept. of Surgery, Royal Infirmary, Sheffield, Nov. 1966.
Borgman, R.F.: Increased survival-time in dystrophic mice treated with methylandrostenediol dienanthoylacetate. Nature (Lond.) 197, 1304 (1963).
Bors, E., Comarr, A.E.: Neurological urology. Basel-München-Paris-New York: S. Karger 1971.
Bottero, A., Lops, M.: L’impiego della dimetazina nelle bronchopneumatopatie specie senile. Gazz. med. ital. 123, 111 (1964).
Bour, H., Tutin, M., Dorf, G., Guy-Grand, B.: La rétinite diabétique: pathogénie et thérapeutique. Ent. Bichat. 1967, 213–220.
Bourdakos, N., Wolf, S.: Creatine and muscular dystrophy; relationship of creatine-creatinine metabolism to diet and drugs. Arch. Neurol. 6, 439–450 (1962).
Bourgeois, M., Vincent, D.: L’oxymétholone. Essai thérapeutique sur 50 malades de neuropsychiatrie. J. Méd. Bordeaux 141, 260–263 (1964).
Brambilla, F., Giardini, M., Russo, R.: Prospects for a pharmacological treatment of phenylketonuria. Dis. nerv. Syst. 36, 257–260 (1975).
Brennan, M.F., Tweedle, D., Moore, F.D.: Body nitrogen after trauma. Lancet 1975I, 38–39.
Bretan, M., Szabo, Z., Jakab, L.: Beeinflussung der diabetischen Retinopathie mit Nor-Andro-stenolonphenylpropionat und Decanoat. Orv. Hetil. 105, 1171–1174 (1964).
Brodsky, I.: The role of androgens and anabolic steroids in the treatment of cancer. Semin. Drug Treatm. 3, No. 1, 15–25 (1973).
Brodsky, I., Dennis, L.H., Kahn, S.B.: Testosterone enanthate (NSC-17591) as a bone marrow stimulant during cancer chemotherapy: Preliminary report. Cancer Chemother. Rep. 34, 59 (1964).
Brodsky, I., Kahn, S.B.: The effect of androgens on cancer chemotherapy. In: Cancer Chemotherapy: Basic and Clinical Applications, 275–287. New York: Grune & Stratton 1967.
Brodsky, I., Kahn, S.B., Conroy, J.F.: The effects of androgens on cancer chemotherapy. In: Cancer Chemotherapy II, 303–314. New York: Grune & Stratton 1972.
Brown, I.A., James, E.M.: Nandrolone-phenpropionate in progressive muscular dystrophy. A preliminary report. Arch. Pediat. 78, 421–431 (1961).
Brown, I.K., Downie, R.J., Haggart, B., Littler, J., Murray, G.H., Robb, P.M., Santer, G.J.: Pharmacological stimulation of fibrinolytic activity in the surgical patient. Lancet 1971I, 774–776.
Browne, P.A.: The treatment of secondary deposits in bone from carcinoma of the breast with P32 and durabolin. Paper read at a Symposium at the University Dept. of Surgery, Royal Infirmary, Sheffield, Nov. 1966.
Brückner, R.: Lentopathie und Retinopathie, Signale im Diabetes und Prädiabetes. Praxis 54, 746–755 (1965).
Brügel, H.: Klinische Erfahrungen bei der Behandlung untergewichtiger Magenresezierter. Aktuelle Kongreß-Berichte 1, 16. Ärztlicher Fortbildungskurs Bad Kissingen. Berlin: Medicus Verlag 1965.
Brügger, W.: Zur Beeinflussung der hämatotoxischen Effekte von Cyclophosphamid durch das anabole Steroid Nandrolonphenylpropionat. Dissertation, Heidelberg, 1967.
Bruhn, H.D., Jipp, P., Okoye, S., Oltmann, A.: Hypofibrinolyse beim akuten Myokardinfarkt. Med. Klin. 69, 1951–1955 (1974).
Buchner, H.: Zur Frage der hormonalen Beeinflussung des posttraumatischen Eiweißverlustes. Wien. med. Wschr. 111, 576–580 (1961).
Buckert, D.: Dianabol in der Geriatrie. Dtsch. med. J. 15, 25–27 (1964).
Bürgi, H., Regit, J.: Zur Ergänzung der tuberkulostatischen Behandlung mit einer Vitamin-Mineral-Anabolikum-Kombination. Praxis 58, 873–874 (1969).
Bullough, W.S.: Mitotic and functional homeostasis—a speculative review. Cancer Res. 25, 1683–1727 (1965).
Bullough, W.S., Homan, J.D.H., Laurence, E.B., Overbeek, G.A.: In vitro Untersuchung an der Mäuseohrepidermis über die von Dexamethason induzierte und von Nandrolondeca-noat aufgehobene Mitosehemmung. J. Endocr. 41, 453–454 (1968).
Burn, J.I., Cooke, W.M.: Effect of nandrolone phenylpropionate (NSC-23162E) on the bone marrow suppression caused by cyclophosphamide (NSC-26271): A clinical trial. Cancer Chemother. Rep. 58, 867–870 (1974).
Burnett, P.C.: A steroidal pyrazole as an anabolic agent in the treatment of geriatric mental patients. J. Amer. Geriat. Soc. 11, 979–982 (1963).
Buttenberg, D.: Anabolika bei gynäkologischen Karzinomen. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.
Castro, J.E., Medawar, P.B., Hamilton, D.N.H.: Orchidectomy as a method of immunopotentiation in mice. Ciba Found. Symp. 18, 237–258 (1973).
Ceccarelli, G.: Anabolizzante e lesione renali. Arch. Sci. med. 120, 374–384 (1965).
Cendrowski, W., Kuran, W.: Results of combined administration of anabolic steroids in patients with multiple sclerosis. Neurol. Neurochir. Psychiat. pol. 6, 573–576 (1972).
Cesnik, H., Fink, E.: Klinische Untersuchungen eines neuen anabolen Steroids. Med. Klin. 59, 1430–1433 (1964).
Chakrabarti, R.: Comparative effects of platelet adhesiveness by phenformin combined with ethylestrenol or stanozolol. Acta Univ. Carol. Med. (Monogr.) (Praha) 53, 261–262 (1972).
Chakrabarti, R., Evans, J.F., Fearnley, G.R.: Effects on platelet stickiness and fibrinolysis of phenformin combined with ethyloestrenol or stanozolol. Lancet 1970I, 591–593.
Chakrabarti, R., Fearnley, G.R.: Phenformin plus ethyloestrenol in survivors of myocardial infarction. Three year pilot study. Lancet 1972II, 556–559.
Chakrabarti, R., Fearnley, G.R.: Pharmacological fibrinolysis in diabetes mellitus. Diabetologia 10, 19–22 (1974).
Chakrabarti, R., Fearnley, G.R., Evans, J.F.: Reduction of platelet stickiness by phenformin plus ethyloestrenol. Lancet 1967II, 1012–1014.
Chakrabarti, R., Fearnley, G.R., Hocking, E.D., Delitheos, A., Clarke, G.M.: Fibrinolytic activity related to age in survivors of myocardial infarction. Lancet 1966I, 573.
Chapuy, P., Convert, G.: Clinical study of strombaject in geriatrics. Cah. méd. Lyon 49, 36 (1973).
Cheng, H., Kohner, E.M., Keen, H., Blach, R.K., Hill, D.W.: Photocoagulation in treatment of diabetic maculopathy. Lancet 1975II, 1110–1113.
Choi, E.S.K., Chung, T., Morrison, R., Myers, C., Greenberg, M.S.: Hypertriglyceridemia in hemodialysis patients during oral dromostanolone therapy for anemia. Amer. J. clin. Nutr. 27, 901–904 (1974).
Christensen, L.R., MacLeod, C.M.: A proteolytic enzyme of serum: characterization, activation, and reaction with inhibitors. J. gen. Physiol. 28, 559–568 (1945).
Christl, H., Brommer, R., Wilde, W., Bork, U.: Moderne eiweißanabole Therapie der täglichen Praxis (I). Fortschr. Med. 80, 667–703 (1962).
Cicchitti, L., Labat, J.C., Introna, L., Minuchin, O.: Accion del deca-noato de nandrolona sobre la retinopatia diabetica. Paper read at Tercer Congreso Argentino de Nutricion, Mendoza, Sept. 1966.
Ciświcka-Sznajderman, M., Berent, H., Rymaszewski, Z.: The effect of combined treatment with phenformin and stanazolol on blood lipids and fibrinolytic activity in patients with hypertriglyceridaemia. Atherosclerosis 19, 153–159 (1974).
Cohen, W.D., Higano, N., Robinson, R.W., LeBeau, R. J.: Changes in serum lipids and urinary ketosteroids during oral and intramuscular administration of androsterone. J. clin. Endocr. 21, 1208 (1961).
Cole, M.P., Todd, I.D.H., Wilkinson, P.M.: Cyclophosphamide and nandrolonedecanoate in the treatment of advanced carcinoma of the breast—results of a comparative controlled trial of the agents used singly and in combination. Brit. J. Cancer 27, 396–399 (1973).
Comar, O.B.: Nuove osservazioni sull’impiego degli steroidi anabolizzanti negli iperazotemici cronici. Minerva urol. 21, 69–74 (1969).
Cooke, W.M., Burn, J.I.: The effect of nandrolone phenylpropionate (Durabolin) on the bone-marrow suppression caused by cyclophosphamide. Brit. J. Surg. 58, 302–303 (1971).
Cooper, I.S., Rynearson, E.H., McCarty, C.S.: Testosterone propionate as a nitrogen-sparing agent after spinal cord injury. J. Amer. med. Ass. 145, 549–553 (1951).
Corona, R.G.: Oximetolona en gastroectomizados. Rev. Med. Mex. 44, 193–199 (1964).
Cottier, P.: Die Anwendung von katabolen und anabolen Hormonen bei Nierenkrankheiten. Dtsch. med. J. 13, 329–334 (1962).
Craig, P.E.: Preliminary report of a long acting anabolic agent, nandrolone decanoate. Clin. Med. 69, 5, 1154–1156 (1962).
Cunliffe, W.J.: An association between cutaneous vasculitis and decreased blood-fibrinolytic activity. Lancet 1968I, 1226–1228.
Cunliffe, W.J., Dodman, B., Roberts, B.E.: Clinical and laboratory double-blind investigation on the effect of fibrinolytic therapy in patients with cutaneous vasculitis. Ann. rheum. Dis. 32, 591–592 (1973).
Cunliffe, W.J., Menon, I.S.: Treatment of Behçet’s syndrome with phenformin and ethyl-oestrenol. Lancet 1969I, 1239–1240.
Dam, F.E., van, Gribnau Overkamp, M.J.H., Benraad, T.J., Haanen, C.A.M.: Over de invloed van enkele geneesmiddelen op het effect en de verwerking van net indirecte anticoa-gulans ethylbiscoumacetaat. Ned. T. Geneesk. 113, 55–56 (1969).
Danowski, T.S., Sabeh, G., Vester, J.W., Sarver, M.E., Sunder, J.H.: Muscular dystrophy. Arch. intern. Med. 115, 294 (1965).
Danysz, A., Kocmierska-Grodzka, D., Panek, R., Matzkovyak, J.: Antimetabolites in the treatment and prophylaxis of radiation sickness. Med. Radiol. Moskva 13, 3–9 (1968).
Dardenne, M.U.: Treatment of retinopathia diabetica with anabolic steroids and light coagulation, and the effect of this therapy on the pathological pattern of free amino acids and protein fractions in serum. Excerpta med. Intern. Congr. Ser. 74, 177 (1964).
Dardenne, P., Cantala, P.: Le traitement de l’involution sénile par un Stéroide anabolisant (oenanthate de méthénolone). Toulouse méd. 65, 787–796 (1964).
Dardenne, U.: Die Therapie der Retinopathia diabetica. Arzneimittel-Forsch. 9, 672 (1959).
Dardenne, U.: The therapeutic applications of anabolic steroids in ophthalmology. Acta en-docr. (Kbh). 63, 143–153 (1961).
Darracott, J.: Treatment of the painful knee fulfilling diagnostic criteria for “chondromalacia patellae”. Curr. med. Res. Opin. 1, 412–420 (1973).
Davidson, J.F., Lochhead, M., McDonald, G.A., McNicol, G.P.: Fibrinolytic enhancement by stanozolol: a double blind trial. Brit. J. Haemat. 22, 543–559 (1972a).
Davidson, J.F., McDonald, G.A., Conkie, J.A.: Fibrinolytic enhancement by stanozolol—a two year study. Brit. J. Haemat. 22, 639–640 (1972b).
Davila Flores, O.E., Herrera, H., Ortega, R.: Effecto anabólico protéinico del decanoato de norandrostenolona. Médico (Méx). 8, 17–19 (1964).
Deineko, N.F., Shustval, N.F., Ikhnenko, R.I., Bakumenko, I.S.: Treatment of peptic ulcer with anabolic hormones. Klin. Med. (Moskau) 51, 57–63 (1973).
Delaney, T.J., Black, M.M.: Effect of fibrinolytic treatment in malignant atrophic papulosis. Brit. med. J. 1975III, 415.
Delmont, J.: Non-tropical sprue. Modern concepts in connection with five cases. Thesis, Marseille, 1961.
Demeulenaere, L.: Erfahrungen mit Methenolon bei Leberzirrhose und chronischer Hepatitis. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.
Derot, M., Bernier, J.J.: “Anuric nephritis”: Treatment of nephropathies with testosterone propionate. Letter to Editor. J. Amer. med. Ass. 145, 47 (1951).
Deutsch, M., Saxena, B.M., Lehmann, H.E.: Combined administration of thioridazine and fluoxymesterone in the treatment of geriatric patients. Curr. ther. Res. 12, 805–809 (1970).
Dieckhoff, J., Schneeweiss, B.: Der Einfluß von katabolen und anabolen Steroiden auf die Antikörperbildung. Dtsch. Gesundh.-Wes. 20, 189–194 (1965).
Dittrich, H., Seifert, E.: Zur Anwendung anaboler Steroide bei Magenresezierten. Med. Klin. 59, 821–823 (1964).
Doane, B.D., Fried, W., Schwartz, F.: Response of uremic patients to nandrolone decanoate. Arch. intern. Med. 135, 972–975 (1975).
Dodman, B., Cunliffe, W.J., Roberts, B.E., Sibbald, R.: Clinical and laboratory double-blind investigations on effect of fibrinolytic therapy in patients with cutaneous vasculitis. Brit. med. J. 1973II, 82–84.
Dontas, S., Papanicolaou, N.T., Papanayiotou, P., Malamos, B.K.: Long-term effects of anabolic steroids on renal functions in the aged subject. J. Geront. 22, No. 3, 268–273 (1967). Dorn, W.: Landarzt 39, 4 (1963).
Dowben, R.M.: Prolonged survival of dystrophic mice treated with 17α-ethyl-19-nortesto-sterone. Nature (Lond.) 184, Suppl. 25, 1966 (1959).
Dowben, R. M.: Muscular dystrophy. Paper read at a Symposium on Anabolic Therapy, Detroit, Michigan, March 1962.
Dowben, R.M.: Treatment of muscular dystrophy with steroids. New Engl. J. Med. 268, 912 (1963).
Dowben, R.M.: Anabole Steroide bei Myopathien. Myopathien. Stuttgart: Georg Thieme Verlag, 1965.
Dowben, R.M., Perlstein, M.A.: Muscular dystrophy treated with norethandrolone. Arch. intern. Med. 107, 245–251 (1961).
Dowben, R.M., Vawter, G.F., Brandfonbrenner, A., Sniderman, S.P., Kaegy, R.D.: Polymyositis and other diseases resembling muscular dystrophy. Arch. intern. Med. 115, 584–594 (1965).
Doyle, A.E., Pinkus, N.B., Green, J.: The use of oxandrolone in hyperlipidaemia. Med. J. Aust. 1, 127–129 (1974).
Dresdale, F.C., Hayes, J.C.: Potential dangers in the combined use of methandrostenolone and sodium warfarin. J. med. Soc. N.J. 64, 609 (1967).
Dubarry, J.J., Auche, Y., Bernard, J.-P., Fontanges, X.: Application thérapeutique des médications anabolisantes en gastro-enterologie à propos du Primobolan-dépôt. Gaz. méd. Fr. 72, 2896–2898 (1965).
Dubarry, J.J., Tournerie, J., Marquier, A.: L’androgénothérapie dans le traitement des cirrhoses. Presse méd. 71, 1311–1313 (1963).
Dubos, G., Hugonat, R.: Therapeutic trial. Strombaject in geriatrics. Lyon méd. 23, 183–186 (1974).
Dudley, H.A.F., Robson, J.S., Smith, M., Stewart, C.P.: The permissive role of adrenal cortical hormones after injury in man. Metabolism 8, 895 (1959).
Dutruel, R.: Sur trente cas de ‘grands vieillards’ malades chroniques traités par l’oxymétholone. Rev. franç. Géront. 11, 59–62 (1965).
Dutz, H., Voigt, K., Wendler, J.: Über die Beeinflußbarkeit der experimentellen Ratten-Ne-phritis durch Testosteron, Oestradiol, Kastration und somatotropes Hormon. Z. ges. inn. Med. 11, 1115–1120 (1956).
Eaton, J.C.: Metabolic effects in chronic renal failure. Proc. roy. Soc. Med. 52, 511–514 (1959).
Eberhardt, G., Möhr, J., Oehlert, W., Schmidt, E., Schmidt, F.W., VondrÁŜek, P.: Kontrollierte Studie zur therapeutischen Wirkung von B-Vitaminen und einem anabolen Steroid bei chronischer Hepatitis. Dtsch. med. Wschr. 100, 2074–2082 (1975).
Edwards, M.S., Curtis, J.R.: Decreased anticoagulant tolerance with oxymetholone. Lancet 1971II, 221.
Efimov, A. S.: Efficacy and mechanism of action of anabolic steroids in diabetic angiopathy. Ter. Arkh. 42, 81–85 (1970).
Efimov, A.S., Karabun, P.M.: Mechanism of action of anabolic steroids in the treatment of diabetes mellitus. Ter. Arkh. 44, 90–94 (1972).
Eger, W.: Experimentelle Untersuchungen zur Frage der Leberschädigung und Oxymetholon im akuten und chronischen Versuch. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.
Ehnholm, G., Huttunen, J.K., Kinnunen, P., Miettinen, T.A., Nikkila, E.A.: Effect of oxandrolone treatment on the activity of lipoprotein lipase, hepatic lipase and phospholipase A1 of human post-heparin plasma. New Engl. J. Med. 292, 1314–1317 (1975).
Ehrlich, H.P., Hunt, T.K.: The effects of cortisone and anabolic steroids on the tensile strength of healing wounds. Ann. Surg. 170, 203–206 (1969).
Ekert, H., Muntz, R.H., Colebatch, J.H.: Decreased anticoagulant tolerance with oxymetholone. Lancet 1971II, 609–610.
Ekisenina, N.I., Krums, L.M., Lukash, L.K., Medvedeva, T.F., Taits, N.S., Fursova, G.A., Chanysheva, R.I.: Nerobol in a complex therapy of chronic enterocolitis. Sovetsk. Med. 35, 68–72 (1972).
El-Abrashi, N., El-Danasonry, M.: Trial of anabolic agents in cases of chronic renal failure with uremia. J. Egypt. med. Ass. 44, 333–339 (1961).
El-Mehairy, M.M., El-Tarabishi, N.: Study of the effect of combining anabolics with steroids in long-term therapy of bronchial asthma. J. Egypt. med. Ass. 43, 646–651 (1966).
Endler, F.: Praktische Erfahrungen mit einem neuen anabolen Wirkstoff in der Orthopädie. Wien. klin. Wschr. 73, 481–485 (1961).
Esposito, R., Pluvio, M., Giordano, D.: Anabolic agents in kidney disease: the effect of forme-bolone on protein synthesis in patients with renal insufficiency or nephrosis. Curr. Med. Res. Opin. 3, 43–45 (1975).
Evans, J.T., Elias, E.G.: The erythropoietic response to anabolic therapy in patients receiving radiotherapy. J. clin. Pharmacol. 12, 101–104 (1972).
Fabrykant, M.: Diabetic retinopathy: Preliminary report on the use of anabolic steroids and high-protein low-fat diets. J. Amer. Geriat. Soc. 10, 743–748 (1962).
Fabrykant, M., Gelfand, M.L., Rosenberg, A.S.: Further experience with anabolic steroids in diabetic retinopathy: Factors precipitating retinal hemorrhages. Amer. J. med. Sci. 248, 304–316 (1964).
Faergeman, O., Damgaard-Federsen, F.: Increase of post-heparin lipase activity by oxandrolone in familial hyperchylomicronemia. Scand. J. clin. Lab. Invest. 31, 27–31 (1973).
Falkson, G., Falkson, H.C., Minnaar, P.C.: A clinical evaluation of stanozolol as an adjuvant to cytostatic treatment of cancer. S. Afr. Cancer Bull. 8, 54–62 (1964).
Fallat, R.: Effects of anabolic and progestational agents upon triglycerides and triglyceride kinetics in normal and hyperlipemic patients. Lipids 9, 117–120 (1974).
Fallat, R.W., Glueck, C.J.: Familial and acquired type V hyperlipoproteinemia. Atherosclerosis 23, 41–62 (1976).
Falliers, C.J., Jorgensen, J.R., Tan, L.S., Bukantz, S.G.: Anabolic effects of stanozolol. Amer. J. Dis. Child. 106, 388–401 (1963).
Fam, A.: The use of anabolizers in urology. J. Egypt. med. Ass. 46, 100–110 (1963).
Fanfani, A., Ricca, M., Cherici, P.: Esperienze di terapia anabolizzante in vecchi TBC. G. Geront. 10, 659–671 (1962).
Fantoli, U., Boccitto, G., Lorenzetti, L.: Azione del fenilpropionato di 19-nor-androstenolone sulla disprotidemia in soggetti affetti da tubercolosi polmonare. Ann. Ist. Forlanini 2, 218–237 (1959).
Fastner, Z.: X. Intern. Congress of Gerontology, Jerusalem (1975). Fauchet, R.: Utilisation du stanozolol chez les malades immobilisés. Sem. Hôp. Paris 70–74 (1966).
Fearnley, G.R.: Ethyloestrenol and postoperative venous thrombosis. Lancet 1973II, 95.
Fearnley, G.R.: Fibrinolysis and deep-vein thrombosis. Lancet 1974I, 454–455.
Fearnley, G.R., Chakrabarti, R.: Increase of blood fibrinolytic activity by testosterone. Lancet 1962II, 128.
Fearnley, G.R., Chakrabarti, R.: Pharmacological enhancement of fibrinolytic activity of blood. J. clin. Path. 17, 328 (1964).
Fearnley, G.R., Chakrabarti, R.: Oral fibrinolytic agents. Brit. med. J. 1968III, 498.
Fearnley, G.R., Chakrabarti, R.: Phenformin and ethyloestrenol for Raynaud’s disease. Lancet 1969II, 1203.
Fearnley, G.R., Chakrabarti, R., Evans, J.F.: Fibrinolytic treatment of rheumatoid arthritis with phenformin plus ethyloestrenol. Lancet 1966II, 757–761.
Fearnley, G.R., Chakrabarti, R., Evans, J.F.: Effect of ethyloestrenol combined with phenformin or with metformin on platelet stickiness and serum-cholesterol in patients with occlusive vascular disease: Lancet 1968II, 1004–1007.
Fearnley, G.R., Chakrabarti, R., Evans, J.F.: Fibrinolytic and defibrinating effect of phenformin plus ethyloestrenol in vivo. Lancet 1969I, 910–914.
Fearnley, G.R., Chakrabarti, R., Evans, J.F.: Mode of action of phenformin plus ethylestrenol on fibrinolysis. Lancet 1971I, 723–725.
Fearnley, G.R., Chakrabarti, R., Hocking, E.D., Evans, J.F.: Fibrinolytic effects of diguanides plus ethyloestrenol in occlusive vascular disease. Lancet 1967II, 1008–1011.
Fenster, L.F.: The nonefficacy of short-term anabolic steroid therapy in alcoholic liver disease. Ann. intern. Med. 65, 738–744 (1966).
Flegel, G.: Beeinflussung des Myocardstoffwechsels durch anabole Substanzen, ihre Verwertung in der Rehabilitationsbehandlung chronischer Herzmuskelschäden. Med. Klin. 57, 519–523 (1962a).
Fiegel, G.: Die reparativen Eigenschaften anaboler Steroide am chronisch geschädigten Myokard. Wien. med. Wschr. 112, 951–954 (1962b).
Fiegel, G., Bargheer, R.: Katamnestische Ergebnisse nach Behandlung Herzkranker mit ana-bolen Steroiden. Med. Klin. 61, 1870–1872 (1966).
Fiegel, G., Bargheer, R., Kukwa, D.: Das Verhalten des Lipidstoffwechsels unter gleichzeitiger Gabe von Anabolika und essentiellen Phospholipiden. Arzneimittel-Forsch. 16, 443–446 (1966).
Fiegel, G., Einfeldt, H.: Die reparativen Eigenschaften anaboler und androgener Steroide in der Rehabilitationsbehandlung von 2546 Herzkranken. Therapiewoche 21, 4042–4046 (1971).
Fiegel, G., Fischer, E.K.: Antitoxisch-anabole Behandlung von Leberschäden. Ärztl. Prax. 11, 1526–1527 (1959).
Fiegel, G., Kelling, H.-W.: Das Verhalten von Nor-Androstenolonphenylpropionat bei schweren Leberschädigungen. Vergleichende Untersuchungen zu früheren Ergebnissen mit Testo-steron-Propionat. Ärztl. Forsch. 13, I/158-I/161 (1959a).
Fiegel, G., Kelling, H.-W.: Die Beeinflussung des schweren Leberparenchymschadens unter Zufuhr hochdosierter Androgenderivate und von Corticosteroiden. Ärztl. Forsch. 13, I/574–I/578 (1959b).
Fiegel, G., Kukwa, D.: Experimentelle Studie über das Verhalten der Blutlipide während längerer Einwirkung verschiedener anaboler Steroide. Arzneimittel-Forsch. 18, 452–456 (1968).
Figueroa, R.B.: Mesterolone in steatosis and cirrhosis of the liver. Acta hepato-gastroenterol. 20, 282–290 (1973).
Fixson, U.: Methenolonoenanthat (Primobolan-Depot) in der postoperativen Behandlung. Med. Welt (Stuttg.) 19, 1109–1114 (1962).
Fixson, U.: Einfluß von Anabolika auf den postoperativen Verlauf. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.
Fixson, U.: Zur Wirkung von Anabolika auf den postoperativen Verlauf nach gynäkologischen Karzinomoperationen. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.
Fölsch, E., Brügger, W., Immich, H.: Zur Beeinflussung der hämatotoxischen Effekte von Cy-clophosphamid durch das anabole Steroid Nortestosteronphenylpropionat. Verh. dtsch. Ges. inn. Med. 73. Kongreß 1967, München: J. F. Bergmann 1967.
Fölsch, E., Brügger, E.W., Brands, W.: Zur Beeinflussung der hämotoxischen Effekte von Cyclophosphamide durch anabole Steroide. Arzneimittel-Forsch. 25, 59–66 (1975).
Fontaine, M., Malmendier, C.L.: Carbohydrate content of human VLDL, IDL, LDL and HDL plasma apoproteins from fasting normal and hyperlipemic patients. Clin. chim. Acta 64, 91–93 (1975).
Forsius, H.: The retinopathic initial symptoms of juvenile diabetes. Acta Ophthal. (Kbh.) 45, 255–256 (1967).
Foss, G.L., Simpson, S.L.: Oral methyltestosterone and jaundice. Brit. med. J. 1959I, 259–263.
Fossard, D.P., Field, E.S., Kakkar, V.V., Friend, J.R., Corrigan, T.P., Flute, P.T.: Fibrinolytic activity and postoperative deep-vein thrombosis. Lancet 1974I, 9–11.
Fossati, C.: Anabolic steroids in the treatment of chronic pulmonary tuberculosis. Panminerva med. 5, 381–383 (1963).
Fossati, C.: Sull’impiego degli steroidi anabolizzanti in terapia. Clin. ter. 70, 169–202 (1974).
Fowler, W.M., Pearson, C.M., Egstrom, G.H., Gardner, G.W.: Ineffective treatment of muscular dystrophy with an anabolic steroid and other measures. New Engl. J. Med. 272, 875–882 (1965).
Foz, M.: Esteroides anabolizantes. I—algunas consideraciones sobre esteroides anabolizantes. Ann. Med. (Med.) 50, 194–202 (1965).
Franken, F.H., Dawecke, H., Gries, E.A., Schweinitz, H.A.v., Holzgrewe, H., Forstmann, U.: Langzeitbehandlung chronischer Lebererkrankungen mit Prednison und Me-thandrostenolon. Dtsch. med. Wschr. 88, 1979–1985 (1963).
Freedman, P., Spencer, A.G.: Testosterone propionate in the treatment of renal failure. Clin. Sci. 16, 11 (1957).
Fröhlich, R., Mumenthaler, M., Wiesendanger, M.: Ergebnisse der Anwendung von anabo-len Hormonen bei myatrophischen Erkrankungen. Praxis 51, 1296–1300 (1962).
Furman, R.H., Howard, R.P., Berkowit, D.: Idiopathic hyperglyceridaemia treated with methyltestosterone and methandienone. Lancet 1963I, 837.
Gabuzda, G.J., Jr., Eckhardt, R.D., Davidson, C.S.: Effect of choline and methionine, testosterone propionate and dietary protein on nitrogen balance in patients with liver disease. J. clin. Invest. 29, 566 (1950).
Gaillard, L., Delphin, D., Ferrat, Y.: La méthode de Nasso: une méthode imprévue mais efficace de prophylaxie de la varicelle en collectivité d’enfants. Pédiatrie 22, 353–355 (1967).
Gautier, E., Tönz, O.: Anaboles Hormon in der Behandlung der Anurie im Kindesalter. Helv. med. Acta 27, 535–538 (1960).
Geoffroy, H., Coudoux, P., Maffioli, C., Chardon, P., Dalle, M.: Etude de l’effet thérapeutique d’un nouvel anabolisant: le bêta (p-hexyloxyphenyl) propionate de 19 nortestosterone, Anador. Gaz. méd. Fr., 77, 3842–3846 (1970).
Gerber, W., Cottier, P.: Zur Wirkung anaboler Hormone auf die Azotämie bei Nierenversagen. Helv. med. Acta 28, 197–215 (1961).
Gerok, W., Sickinger, S., Hennekeuser, H.H. (Hrsg.): Alkohol und Leber. Stuttgart-New York: Schattauer 1971.
Gerritzen, F. M.: Diabetische retinopathie. Ned. T. Geneesk. 119, 964–969 (1975).
Gessner, P.K., Gessner, T.: The interaction of barbital and testosterone relative to their hypnotic effects. Arch. int. Pharmacodyn. 201, 52–58 (1973).
Geyer, G., Jesserer, H.: Kann der gesteigerte Eiweiß-Katabolismus während einer Cortisonthe-rapie durch anabole Steroide ausgeglichen werden? In: Die endokrine Behandlung des Mamma- und Prostatacarcinoms. Endokrine Regulationen des Kohlehydratstoffwechsels. Berlin-Göttingen-Heidelberg: Springer 1961.
Geyer, G., Jesserer, H.: Ergebnisse und Probleme der Therapie mit eiweißanabolen Steroiden, diskutiert an Erfahrungen mit Methandrostenolon (Dianabol/Ciba). Dtsch. Arch. klin. Med. 208, 252–278 (1962).
Gherondache, C.N., Dowling, W.J., Pincus, G.: Metabolic changes induced in elderly patients with an anabolic steroid oxandrolone. J. Geront. 22, 290 (1967).
Ghione, M.: Anti-infective action of an anabolic steroid. Proc. Soc. exp. Biol. 97, 773–775 (1958).
Gibba, A., Petterino, E.: Studio sull’azione renoprotettiva di un nuovo Steroide anabolizzante: il 19-nor-androstenolone decanoato. Minerva urol. 14, 3–15 (1962).
Giles, A.R.: Fibrinolytic activity and deep-vein thrombosis. Lancet 1974I, 803.
Gilliam, J.N., Herndon, H., Prystowsky, S.D.: Fibrinolytic therapy for vasculitis of atrophie blanche. Arch. Derm. Symp. (Chic.) 109, 664–667 (1974).
Girolami, M.: La cirrosi del fegato può guarire clinicamente in una alta percentuale di casi con trattamento a base di testosterone e vitamina B1 ad alte dosi. Minerva med. 64, 1567–1623 (1973).
Gjorup, S., Thaysen, J.H.: The effect of anabolic steroid (Durabolin) in the conservative management of acute renal failure. Acta med. scand. 167, 227–238 (1960).
Glueck, C.J.: Progestins, anabolic-androgens, estrogens: effects on triglycerides and lipases. Clin. Res. 17, 475 (1971a).
Glueck, C.J.: Effects of oxandrolone on plasma triglycerides and postheparin lipolytic activity in patients with types III, IV, and V familial hyperlipoproteinemia. Metabolism 20, 691–702 (1971b).
Glueck, C.J., Fallat, R.W., Mendoza, S.: Effect of sex hormones on protamine inactivated and resistant post-heparin plasma lipases. Clin. Res. 23, 498A (1975).
Glueck, C.J., Ford, S., Fallatt, R., Steiner, P.: Triglyceride removal efficiency and lipases: Effects of oxandrolone. Circulation 46, Suppl. II, 263 (1972).
Glueck, C.J., Ford, S., Steiner, P., Fallat, R.: Triglyceride removal efficiency and lipoprotein lipases—effects of oxandrolone. Metabolism 22, 807 (1973).
Glueck, C.J., Steiner, P., Swanson, P.: Amelioration of endogenous hyperglyceridemia by nor-ethindrone acetate and oxandrolone. Clin. Res. 18, 454 (1970a).
Glueck, C.J., Swanson, F., Hutsell, T.: Effects of oxandrolone and norethindrone acetate on tissue and plasma lipases, and triglycerides. Circulation 42, Suppl. 3, 158 (1970b).
Glueck, H.I., Glueck, C.J.: Clotting mechanism in patients with hypertriglyceridemia during therapy with anabolic or progestational drugs. Clin. Res. 18, 611 (1970).
Glueck, H.I., Glueck, C.J.: Clotting mechanism in patients with hypertriglyceridemia during therapy with anabolic or progestational drugs. Thrombos. Diathes. haemorrh. (Stuttg.) 29, 499–509 (1973).
Goebel, F.-D.: Diabetes mellitus und Mikroangiopathie. Dtsch. med. Wschr. 100, 382–385 (1975).
Gokhale, B.B., Kotnis, M.G., Kasabedar, P.V.: A preliminary note on anabolic therapy in leprosy. J. trop. Med. Hyg. 67, 284–285 (1964).
Goldenberg, I.S., Sedransk, N., Volk, H., Segaloff, A., Kelley, R.M., Haines, C.R.: Combined androgen and antimetabolite therapy of advanced female breast cancer. Cancer 36, 308–310 (1975).
Goldman, A.G., Zarday, Z.: Effects of oxandrolone in advanced renal insufficiency. N.Y. St. J. Med. 73, 316–319 (1973).
Goldstein, J., Combes, B.: The effect of steroids on the activity of the enzyme that catalyzes sulfobromophthalein-glutathione conjugation. J. Lab. clin. Med. 67, 830–835 (1966).
Gomes, J.M.P., Lagreca, J.R., Moraes, C.R.: Emprêgo de anabolisante em cirurgia cardiaca. Hospital (Rio de J.) 78, 139–145 (1970).
Gonnard, P., Lefranc, G., Gosse, R., Paris, E.: Recherches sur les propriétés protéino-anaboli-santes de l’androstanolone base. Sem. Hôp. Paris 33, 1 (1957).
Goodman, J., Bessman, A.N.: Effect of nortestosterone decanoate on red cell 2, 3 diphosphogly-cerate and hematocrit in hemodialysis patients. Clin. Pharmacol. Ther. 17, 167–170 (1975).
Gorokhovsky, B.I., Kitaeva, I.T.: The use of anabolic hormones in myocardial infarction. Klin. Med. (Moskau) 48, 29–34 (1970).
Gramsch, H.: Klinischer Beitrag über die Anwendung von Primobolan bei Hepatopathien. Med. Welt (Stuttg.) 1963IV, 212–214.
Gramsch, H.: Beobachtungen über die orale Methenolontherapie bei Hepatopathien. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.
Gribbin, H.R., Flavell Matts, S.G.: Mode of action and use of anabolic steroids. Brit. J. clin. Pract. 30, 3–5, 7–9 (1976).
Grönberg, A., Svanteson, G.: Svenska Laekartidn. 48, 2005 (1951) cited in W. Nordlöw, A. GrÖnberg, G. Svanteson: Sexualhormonterapi vid retinopathia diabetica. Nord. Med. 49, 742–744 (1953).
Grossman, J., Yalow, A.A.: Effects of anabolic steroids on albumin metabolism. J. clin. Endocr. 25, 698–707 (1965).
Gudbjarnason, S., Fenton, J.C., Wolf, P.L., Bing, R.J.: Stimulation of reparative processes following experimental myocardial infarction. Arch. intern. Med. 118, 33–40 (1966).
Gürtler, J.: Untersuchungen über die Möglichkeit der Steigerung des Körpergewichts mit Stromba. Praxis 52, 900–902 (1963).
Haberler, H., Pateisky, K.: Dystrophia musculorum progressiva: Results of clinical and biochemical examinations in the course of treatment with an anabolic substance (norandrosten-olondecanoate). Excerpta med. Int. Congr. Ser. 38, 161–162 (1961).
Hagenbuchner, K.: Über den Anwendungsbereich anabol wirksamer Steroide in der Neurologic. Wien. klin. Wschr. 74, 214–219 (1962).
Haggenmüller, F.: Anabole Steroide bei Kindern mit nephrotischem Syndrom. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.
Haggenmüller, F.: Wirkung der Anabolikumbehandlung bei einem Kind mit Debré-de Toni-Fanconi-Erkrankung und Zystin-Speicherkrankheit. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.
Hamerski, W.: Durabolin in the treatment of diabetic proliferative angioretinopathy. Klin. oczna 44, 461–465 (1974).
Hamilton, L.D., Bennett, J.L., Silver, J.: Nandrolone phenpropionate in the treatment of geriatric patients with chronic brain damage. J. Amer. Geriat. Soc. 12, 373–378 (1964).
Hamilton, M.: Lectures on the Methodology of Clinical Research, 2nd Ed. Edinburgh-London: Churchill Livingstone 1974.
Hammer, F.: Zur Behandlung von Altersherzerkrankungen mit anabolen Steroiden. Med. Welt. (Stuttg.) 17, (N.F.) 2814–2817 (1966).
Hansten, Ph.D.: Drug Interactions, 2nd Ed. Philadelphia: Lea & Febiger 1973.
Hantschmann, N., Matzelt, D., Mertens, H.G., Nowakowski, H.: Zur Behandlung von Muskelkrankheiten mit anabolen Steroiden. Dtsch. med. Wschr. 87, 2619–2634 (1962).
Harn, C.S.: Clinical experiences with Winstrol. M.D. Journal 12, 154–161 (1963).
Harris, E.L., Fitzgerald, J.D.: The Principles and Practice of Clinical Trials. Edinburgh-London: E. & S. Livingstone 1970.
Hartenbach, W.: Indikationen und Kontraindikationen für die Anwendung kataboler und ana-boler Hormone in der Chirurgie. Münch. med. Wschr. 104, 1567–1574 (1962).
Haslock, D.I., Wright, V.: A corticosteroid-sparing agent in rheumatoid arthritis. A trial of nandrolone decanoate (Deca-Durabolin). Clin. Trials J. 4, 31–34 (1971).
Hecht, Y.: Traitement de l’insuffisance hépatocellulaire des cirrhoses par les anabolisants. Rev. franç. Gastro-Entérol. 65, 51–61 (1971).
Hedner, U., Nilsson, I.M., Isacson, S.: Phenformin and ethyloestrenol in recurrent deep venous thrombosis. Presented at 10. Erfurter Konferenz über Hämostase und Thrombose, Mai 1975. Folia haemat. (Lpz.) In press. (1975a).
Hedner, U., Nilsson, I.M., Isacson, S.: Effect of ethyloestrenol on fibrinolysis in the vessel wall. Thrombos. Diathes. haemorrh. (Stuttg.) 34, 609 (1975b).
Hellmann, L., Bradlow, H.L., Zumoff, B., Fukushima, D.K., Gallagher, T.F.: Thyroid-an-drogen interrelations and the hypocholesteremic effect of androsterone. J. clin. Endocr. 19, 936 (1959).
Hendler, E.D., Goffinet, J.A., Ross, S., Longnecker, R.E., Bakovic, V.: Controlled study of androgen therapy in anemia of patients on maintenance hemodialysis. New Engl. J. Med. 291, 1046–1051 (1974).
Henkes, H.E., Riaskoff, S., Houtsmuller, A.J.: Nieuwe ontwikkelingen in de behandeling van de diabetische retinopathie. Ned. T. Geneesk. 115, 1765–1769 (1971).
Herk, E.J., van: An investigation of the effect of the steroid ethylestrenol on facial hairgrowth. Acta endocr. 41, 407–410 (1962).
Herrmann, J.B., Woodward, S.C.: An experimental study of wound healing accelerators. Amer. Surg. 38, 26–34 (1972).
Heyck, H., Laudahn, G., Lüders, C.J., Müller-Stephann, H., Schmidt-Peter, P.: Anabolic steroids and digitoxin in the treatment of progressive muscular dystrophy. Acta paediat. scand. 54, 205–217 (1965).
Hiekkala, H.: The influence of anabolic hormones on retinopathy in juvenile diabetics. Diabetologia 1, 134 (1965).
Hirayama, C., Kimura, N., Masuya, T.: Anabolic steroid effect on hepatic protein synthesis in patients with liver cirrhosis. Digestion 3, 41–47 (1970).
Hock, C.W.: Medical treatment of the functionally ill geriatric patient. Geriatrics 16, 182–184 (1961).
Hofmann, H., Zeppek, E.: Über die Behandlung der Retinopathia diabetica mit einem anabolen Steroid. Klin. Mbl. Augenheilk. 143, 821–832 (1963).
Honegger, H., Bohleber, U.: Klinik und Therapie der Retinopathia diabetica. Med. Mschr. 25, 298–308 (1971).
Horky, J.: The use of anabolic steroids in the treatment of liver diseases. T. Gastroent. 10, 109–126 (1967).
Horn, Y.: Leucopoietic properties of four different androgenic hormones in irradiated rats. Scand. J. Haemat. 8, 470–475 (1971).
Houtsmuller, A.J.: The therapeutic applications of anabolic steroids in ophthalmology: biochemical results. Acta endocr. (Kbh.) Suppl. 63, 154–169 (1961).
Houtsmuller, A.J.: Influence of deca-durabolin on the usual course of the glucose tolerance test in diabetes. Diabetologia 1, 80 (1965).
Houtsmuller, A.J., Henkes, H.E.: Klinische und biochemische Effekte von Nandrolon phenyl-propionat (Durabolin) und Nandrolondecanoat (Deca-Durabolin) bei diabetischer Retinopathie. Ber. dtsch. Ophthal. Ges. 63, 57–62 (1960).
Houtsmuller, A.J., Henkes, H.E.: Clinical investigations of patients with diabetic retinopathy treated with anabolic steroids. Paper presented at the Vth Congress of the International Diabetes Federation, Toronto, July, 1964.
Houtsmuller, A.J., Henkes, H.E., van Poppel, A.L.A.: Clinical investigation of patients with diabetic retinopathy treated with anabolic steroids. Paper read at the Joint Congress Irish Ophthalmological Society—British Diabetic Society, Dublin, April 1963.
Houtsmuller, A.J., van Poppel, A.L.A.: Treatment of diabetic retinopathy with anabolic steroids. Ophthalmologica (Basel) 145, 185–206 (1963).
Huber, E.G.: Therapeutische Erfahrungen mit anabolen Hormonen. Münch. med. Wschr. 103, 1133 (1961).
Huguet, F.-J.-D., Tournigand, P., Duran, G.: Effets de l’androstanolone-base sur 120mala-des. Presse méd. 69, 2433–2434 (1961).
Hunter, P.R., Cotton, S.G., Kelsey, J.H., Blooms, A.: Controlled trial of methandienone in treatment of diabetic retinopathy. Brit. med. J. 1967III, 651–653.
Huseman, C., Johanson, A.: Growth hormone deficiency in anorexia nervosa. J. Pediat. 87, 946–948 (1975).
Hussar, D.A.: Drug interactions. Amer. J. Pharm. 145, 65–116 (1973).
Hvidberg, E.F., Dayton, P.G., Read, J.M., Wilson, C.H.: Studies of the interaction of phenylbutazone, oxyphenbutazone, and methandrostenolone in man. Proc. Soc. exp. Biol. (N.Y.) 129, 438–443 (1968).
Igari, J., Hayashi, Y., Ushio, M., Miki, S., Iwado, M.: The effect of long-term administration of anabolic steroid upon total serum cholesterol level. Jap. J. Geriat. 3–4, 275–282 (1966).
Igic, R., Jelicic, J., Nikulin, E., Stern, P.: Myotrophischer Effekt des Metenolazetat auf die experimentelle Muskeldystrophie der Ratte. Endokrinologie 54, 103–106 (1969).
Iisalo, E., Kasanen, A., Karki, N., Tala, E.: The effect of an anabolic steroid, nor-testosterone phenyl propionate (durabolin), on the urinary and plasma steroids in patients with normal and decreased renal function. Acta med. scand. (Kbh.) 171, 183–186 (1962).
Iovine, G., Gierson, H.W.: Methandrostenolone as an anabolic agent in emphysema. Curr. ther. Res. 5, 219–231 (1963).
Isacson, S., Nilsson, I.M.: Effect of treatment with combined phenformin and ethyloestrenol on the coagulation and fibrinolytic systems. Scand. J. Haemat. 7, 404–408 (1970).
Jaffe, M.D.: Ethylestrenol, coronary artery disease and collaterals. Clin. Res. 21, 813 (1973).
Jaffe, M.D.: Improvement in postexercise “ischemic” electrocardiographic changes by testosterone cypionate treatment. Clin. Res. 22, No. 4, 595A (1974).
James, V.H.T., Landon, J., Wynn, V.: Effect of an anabolic steroid (methandienone) on the metabolism of Cortisol in the human. J. endocr. (Kbh.) 25, 211–220 (1962).
Jannuzzi, C., Bassetti, D., Frigerio, G.: Ricerche cliniche controllate sull’effetto di steroidi ana-bolizzanti nell’epatite virale. Minerva med. 61, 1902–1911 (1970).
Japa, J., Narbutt, B., Hankiewicz, J., Stas, J.: The influence of encorton and of dianabol administration on protein metabolism in Addison’s disease. Endokr. pol. 17, 1–10 (1966).
Jefimov, A.S.: Die Behandlung der diabetischen Angiopathien. IV. Internationales Donau-Sym-posium über Diabetes mellitus, Dubrovnik, Abstract 133 (1975).
Johnston, I.D.A., Burn, J.I.: The effect of nandrolone (durabolin) on the white cell counts of rats treated with chlorambucil. Paper read at a Symposium at the University Dept. of Surgery, Royal Infirmary, Sheffield, Nov. 1966.
Johnson, P.C., Jr.: Weight gain in geriatric patients. Paper presented at a Symposium on Anabolic Therapy, Detroit, Michigan, March 1962.
Johnson, R.H., McLellan, D.L.: Multiple sclerosis. Practitioner 209, 183–190 (1972).
Jones, C.R., van Itallie, T.B., Stevenson, S.S., Pigman, W.W.: Decrease in hydroxyproline excretion in a patient with Marfan’s syndrome after methandrostenolone therapy. J. Amer. med. Ass. 207, 2085–2086 (1969).
Jose, A.D., Mitchell, A. S.: Elevation of serum cholesterol by an anabolic steroid. Lancet 1964I, 473–474.
Jungck, E.C., Greenblatt, R.B.: Methandrostenolone, an oral anabolic agent. Sth. med. J. (Bgham, Ala.) 57, 909–913 (1964).
Kaeser, H.E.: Zur Frage der Behandlung der Myopathien mit Sexualhormonen und ihren Deri-vaten. Nervenarzt 32, 38–40 (1961).
Kahn, S.B., Conroy, J.F., Brodsky, I.: Effect of nandrolone phenpropionate on myelopoiesis. J. med. exp. Clin. 5, 303–309 (1974).
Kaiser, H.: Cortisonderivate in Klinik und Praxis. 6th Ed., Stuttgart: Thieme 1973.
Kalliomäki, J.L., Markkanen, T.K., Pirila, A.M., Ruikka, I.: Norandrostenolone decanoate— a new anabolic steroid with prolonged effect. Ann. med. intern. fenn. 50, 178–184 (1961a).
Kalliomäki, J.L., Pirilä, A.M., Ruikka, I.: A therapeutic trial with ethyl-estrenol in geriatric patients. Acta endocr. (Kbh.) Suppl. 63, 124–128 (1961b).
Kalliomäki, J.L., Seppälä, P.: Norandrostenolone decanoate as a cardiac anabolizer studied by means of electrocardiographic changes. Cardiologia 43, 124–128 (1963).
Karjala, R.J., Ford, R.V.: Prolonged anticatabolic activity of nandrolone decanoate during corticosteroid therapy. Geriatrics 19, 511–516 (1964).
Kasich, A.M.: Clinical evaluation of nandrolone phenpropionate in patients with gastrointestinal disease. Amer. J. Gastroent. 40, 628–633 (1963).
Kerreijn, K.F., Delver, A.: Ethylestrenol (Orgabolin): Effects on asthmatic children during corticosteroid treatment. Scand. J. Resp. Dis. Suppl. 68, 70–77 (1969).
Kessel, M.: Untersuchungen über den Einfluß anaboler Substanzen auf die Stickstoff-Retention bei akutem Nierenversagen. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.
Kill, J.M.: Behandlung einer an Brustkrebs Erkrankten mit Endoxan und anabolem Hormon. Erfahrungsbericht. Münch. med. Wschr. 103, 1767–1768 (1961).
Kink, R.: Über die Wirkung anaboler Steroide beim Diabetes mellitus. Med. Mschr. 16, 463–467 (1962).
Kirk, J., Handley, D.A.: Experiences in the use of fibrinolytic agents in Behçet’s syndrome. Aust. J. Derm. 13, 5–10 (1972).
Kleibel, F.: Die Wirkungen von Androstan-17β-ol-3-on auf den Stoffwechsel Karzinomkranker während der Strahlenbehandlung. Strahlentherapie 118, 446–453 (1962a).
Kleibel, F.: Die anabole Wirkung von Norsteroiden und Ethylestrenol in der Strahlenbehandlung. Munch. med. Wschr. 104, 2514–2518 (1962b).
Kleibel, F.: Die Behandlung kataboler Zustände in der Radiologic Med. Welt 47, 2529 (1962c).
Kleibel, F.: Wirkung von Anabolika auf den Stoffwechsel Tumorkranker während der Strahlentherapie. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964a.
Kleibel, F.: Klinische Veränderungen am Eiweiß-, Stickstoff-, Nukleoproteid-, Purin-, Phosphor-, Elektrolyt-und Wasserhaushalt während der Strahlentherapie. In: Einführung in die klinisch-experimentelle Radiologic. München-Berlin: Urban & Schwarzenberg 1964b.
Kleibel, F.: Langwirkendes Anabolikum (Clinibolin) als Adjuvans in der Tumortherapie. Münch. med. Wschr. 111, 2452–2454 (1969).
Kleibel, F.: Klinische Ergebnisse der Kombinationsbehandlung von 32Phosphor und Anabolika bei multiplen Knochenmetastasen. Fortschr. Röntgenstr. 116, 66–67 (1972).
Kliaczko, W.R., Tirkina, T.N., Michajlowa, I.N.A.: Diabetic retinopathy and its complex treatment with particular reference to therapy with anabolic steroids. Endokr. pol. 21, 383–392 (1970).
Kluthe, R.: Die N-Bilanz bei nephrotischem Syndrom unter verschiedenen Steroiden. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.
Kluthe, R., Lampe, J.: Experimenteller Beitrag zur Strahlentherapie der Ratten-Masugi-Ne-phrose. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.
Klyachko, V.R., Tirkina, T.N., Ryabchuk, O.G., Mazovetsky, A.G.: Treatment of diabetic retinopathies. Probl. Endokr. 17, 25–30 (1971).
Kochakian, C.D.: A comparison of the renotrophic with the androgenic activities of various steroids. Amer. J. Physiol. 142, 315–325 (1944).
König, H.: Behandlung der Retinopathia diabetica. Dtsch. med. Wschr. 97, 1196 (1972).
Kolodny, A.L.: Methandrostenolone (Dianabol) in the clinical management of weight deficit. Med. Tms (N.Y.) 91, 9–19 (1963).
Komarov, F.I., Lisovsky, V.A., Lisovsky, I.V., Schedrunov, V.V.: The effect of nerobol and aminocrovin on the free amino acids content in peptic ulcer. Sovetsk. Med. 36, 83–87 (1973).
Konrad, R.M., Ammedick, U., Hupfauer, W., Ringler, W.: Der Effekt anaboler Steroide auf die Stickstoffbilanz bei Patienten nach Lungenoperationen. Chirurg 38, 168–171 (1967).
Kopera, H.: Über therapeutische Versuche mit anabolen Steroiden bei diabetischer Retinopa-thie. Abhandl. dtsch. Akad. Wiss. Berlin Kl. Med. 3, 361–404 (1964).
Kopera, H.: Clinical Experiences with Anabolic Steroids in some Special Indications. Hormonal Steroids, Biochemistry, Pharmacology and Therapeutics, Vol.2, pp.195–200. New York: Academic Press 1965.
Korst, D.R., Bowers, C.Y., Flokstra, J.H., McMahon, F.G.: Clinical evaluation of a new anabolic agent 7α, 17α-dimethyltestosterone (bolasterone). Clin. Pharmacol. Ther. 4, 734–739 (1963).
Kracht, J.: Anabole Hormone und sekundäre Nebennierenrindenatrophie. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.
Kral, V.A., Wigdor, B.T.: Androgen effect on senescent memory function. Geriatrics 14, 450–456 (1959).
Krizek, V., Stepanek, P., Sadilek, L.: Starvation and anabolic steroids. Metab. Clin. Exp. 18, 585–592 (1969).
Kroath, F.: Zur Behandlung der Presbyakusis mit Sexualhormonen. Z. Laryng. Rhinol. 46, 552–555 (1967).
Krotov, V.P.: The effect of anabolic steroids on the course of uremia. Bull. exp. biol. Med. 62, 34–37 (1966).
Kruskemper, H.-L.: Anabolic Steroids. New York-London: Academic Press 1968.
Kruskemper, H.-L.: Androgene, anabole Steroide und Fettstoffwechsel. Z. Ernährungsw. Suppl. 12, 16–21 (1972).
Kruskemper, H.-L., Reichertz, P.: Der Einfluß eines anabol wirksamen Steroids (1-Methyl-17β-hydroxy-5a-androst-l-en-3-on) auf Veränderungen des Elektrokardiogramms bei experi-menteller Hyperthyreose. Z. ges. exp. Med. 137, 85 (1963).
Krums, L.M.: Dynamic changes of some protein metabolism indices in patients with chronic enterocolitis against the background of nerobol medication. Vop. Pitan. 30, 44–46 (1971).
Küchle, H. J.: Diabetes und Auge. Med. Welt 18, 1985–1988 (1967).
KÜhn, W.: Über die Wirkung einer neuartigen anabol wirksamen Substanz (1-Methyl-Δ 1-an-drostenolönanthat) auf die Ernährungsverhältnisse bzw. den Verlauf tuberkulöser Lungener-krankungen. Dissertation, Med. Akad. Düsseldorf 1964.
Kuemmerle, H.P., Garrett, E.R., Spitzy, K.H.: Klinische Pharmakologie und Pharmakothera-pie. 3rd ed., München-Berlin-Wien: Urban & Schwarzenberg 1976.
Kuhn, E.: Progressive Muskeldystrophie, Myotome, Myasthenic: Gespräch über die Therapie der progressiven Muskeldystrophie (Gesprächsleitung: R.Beckmann), pp.145–155. Berlin-Heidelberg-New York: Springer 1966.
Kulcsar-Gergely, J., Kulcsar, A., Kiss, A.: The role of sex differences in the effect of anabolics on the liver. Arzneimittel-Forsch. 25, 417–420 (1975).
Kuo, P.T., Quick, R.E.: Improvement of hypertriglyceridemia by anabolic agent in primary type I hyperlipoproteinemia. Circulation 42, Suppl. 3, 18 (1970).
Kutschera, E.: Probleme der diabetischen Retinopathie. Wien. klin. Wschr. 82, 706–710 (1970).
Kutschera-Aichbergen, H.: Anabolika bei biochemischen Myokardschäden. Wien. med. Wschr. 116, 352–354 (1966).
Kutzsche, A.: Experimentelle Beeinflussung von Tierinfektionen durch Methenolonester. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.
Kuzell, W.C.: Methandrostenolone in rheumatic diseases and osteoporosis. Geriatrics 17, 428–441 (1962).
Lachnit, K.S., Zwerina, R.: Zur Frage der Anwendung anaboler Steroide in der Geriatric Münch. med. Wschr. 107, 1125–1128 (1965).
Lampitella, P.: Gli steroidi anabolici nel trattamento dell’ulcera sperimentale alla Shay. Boll. Soc. ital. Biol. sper. 40, 1584–1587 (1964).
Lancet Editorial: Lipid-lowering drugs after myocardial infarction. Lancet 1975I, 501–502.
Landon, J., Wynn, V., Samols, E.: The effect of anabolic steroids on blood sugar and plasma insulin levels in man. Metabolism 12, 924 (1965).
Langnickel, D.: Zur Behandlung von Malignomen mit Tris-Äthyleniminobenzochinon, 19-Norandrostenolon-Decanoat und Prednison. Med. Welt 18, 1015–1022 (1963).
Langsch, H.-G.: Zur Frage der Beeinflussung des Kohlehydratstoffwechsels bei Diabetikern durch Oral-Turinabol. Medicamentum 11, 106–107 (1970).
Laurence, D.R.: Clinical Pharmacology. 4th Ed. Edinburgh-London: Churchill Livingstone 1973.
Laurijssens, M., Vuylsteek, K., Vermeulen, A.: Progressive myopathische dystrofie. Belg. T. Geneesk. 16, 774–784 (1960).
LeBeau, R.J., Robinson, R.W.: Effect of an anabolic steroid on hyperlipemia. Cardiovasc. Res. VI. World Congr. Cardiol. 196 (1970).
Leevy, C.M.: Fatty liver: A study of 270 patients with biopsy proven fatty liver and a review of the literature. Medicine (Balt.) 41, 249 (1962).
Leevy, C.M.: Abnormalities of hepatic DNA synthesis in man. Medicine 45, 423–433 (1966).
Leevy, C.M.: Clinical diagnosis, evaluation and treatment of liver disease in alcoholics. Fed. Proc. 26, 5, 1474–1481 (1967).
Leevy, C.M.: Cirrhosis in alcoholics. Med. Clin. N. Amer. 52, 6, 1445–1455 (1968).
Leevy, C.M.: Therapie der Alkoholfettleber und Hepatitis. Therapiewoche 20, 2396–2398 (1970).
Lefrançois, J.-J.: De l’emploi d’un stéroide anabolisant en milieu neuro-psychiatrique. Rev. Neuropsichiat. Ouest 12, 17–27 (1966).
Leschinsky, L.A., Kharitonova, V.V.: Experience in the therapeutic employment of nerobol in combination with potassium salts in patients with the syndrome of chronic coronary insufficiency. Klin. Med. 48, 38–42 (1970).
Leschinsky, L.A., Kharitonova, V.V.: Combined therapy with nerobol and potassium salts in ischemic disease of the heart. Terap. Arkh. 44, 40–44 (1972).
Leschinsky, L.A., Pevchikh, V.V., Petrov, N.M.: The use of methylandrostendiol in myocardial dystrophies and atherosclerotic cardiosclerosis. Ter. Arkh. 39, 84–87 (1967).
Leschinsky, L.A., Pevchikh, V.V., Trusov, V.V., Vakhrushev, Y.M., Verevkin, A.M.: Comparative investigation into the effectiveness of nerobol and quateron as well as their combinations in gastric and duodenal ulcers. Klin. Med. (Moskau) 50, 68–73 (1972).
Leyritz, M.J., Capron, C., Capron, H., Sanchez, F., Timsit, M.: Action favorable du P.P.N.A. chez les malades atteintes de démence de la sénilité. Ann. méd.-psychol. 5, 1–3 (1961).
Lindner, H.: Zum Verhalten von Bilirubin, alkalischer Phosphatase, Transaminasen (GOT und GPT) und des Bromsulfophthaleintestes bei Patienten mit Leberzirrhose und chronischer Hepatitis unter peroraler Primobolan-Therapie. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964a.
Lindner, H.: Klinische Beobachtungen über Langzeitbehandlung mit Primobolan. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964b.
Lindner, H.: Langzeittherapie der Leberzirrhose mit anabolen Steroiden. Med. Klin. 62, 59–64 (1967 a).
Lindner, H.: Treatment of liver cirrhosis with anabolic steroids. Recent Advanc. Gastroenterol. 3, 662–664 (1967b).
Linet, O.: Interactions between androgenic-anabolic steroids and glucocorticoids. Fortschr. Arz-neimittel-Forsch. 14, 139–195 (1970).
Lineva, V.A.: On the correcting effect of anabolic preparations on the protein composition of the blood in patients with acute coronary insufficiency. Kardiologija 11, 75–78 (1971).
Liotta, S., Scandariato, V., de Laurenzi, A.: Influenza del prednisone e degli steroidi anaboliz-zanti sulla risposta anticorpale ad antigeni stafilococcici. Progr. med. 23, 432–435 (1967).
Little, P.J., Bailey, R.R.: Effect of tetracyclines on level of blood urea in patients with renal failure. Aust. Ann. Med. 19, 88 (1970).
Littmann, L.: Changes of glucose tolerance and plasma immunoreactive insulin level before and after treatment of type IV and type V hyperlipoproteinemia with oxandrolone. Diabetologia 10, 396 (1974).
Lods, J.-C.: Intérêt d’un nouvel anabolisant à action prolongée en gastro-entérologie. Gaz. méd. Fr. 71, 3338–3339 (1964).
Loewit, K.: Über den Einfluß anaboler Hormone auf die Folgen einer Strahlenschädigung bei der weißen Maus. Strahlentherapie 125, 281–298 (1964).
Lomazova, M.M.: Methyluracil and nerobolin in the antirecurrence treatment of patients with ulcer disease. Vrach. Delo 1, 56–57 (1973).
Longridge, R.G.M., Gilliam, P.M.S., Barton, G.M.G.: Decreased anticoagulant tolerance with oxymetholone. Lancet 1971II, 90.
Lorimier, A.A., de, Gordan, G.S., Lowe, R.C., Carbone, J.V.: Methyltestosterone, related steroids and liver function. Arch. intern. Med. 116, 289–294 (1965).
Louyot, P., Gaucher, A., Benoit, P.: Etude clinique d’un nouvel anabolisant, le stanozolol. Ann. méd. Nancy 4, 203–211 (1965).
Lundberg, P.O., Blom, S.: Behandling av muskeldystrofier med anabola steroider. Opusk. med. (Stockh.) 8, 125–129 (1963).
MacMaster, D.R., Alamin, K.: Treatment of severe weight loss with methandrostenolone—a less virilizing anabolic agent. Amer. J. Psychiat. 120, 179–180 (1963).
Maggi, C., Barbi, G.: Lo stato nutritionale proteico del bronchitico cronico. Arch. Sci. med. 110, 668 (1960).
Makarov, G.A.: The mechanism of disturbances of synthetic processes in tissues in prolonged hypodynamia. Patol. Fiziol. Eksp. Ter. 4, 41–45 (1974).
Mall, G., Heilbrunn, A., Paarmann, H.F., Junemann, H.J., Rheingans, W.R.: Die Behand-lung der multiplen Sklerose mit anabolen Steroiden. Med. Klin. 63, 2075–2077 (1968).
Manai, G., Piccinini, G.: La metazina capronato (2-metil-5-androstan 17-ol-3, 3’-azina-17-cap-ronato) in terapia geriatrica. G. Geront. 19, 357–367 (1971).
Mandal, B.K., McNulty, M.: Treatment of haemolytic-uraemic syndrome with phenformin and ethyloestrenol. Lancet 1971II, 1036.
Markiewicz, K.: Durabolin in the management of nephrotic syndrome. Wiad. lek. 18, 661–664 (1965).
Markov, M.I., Piralov, G.V.: Use of corticosteroids and anabolic steroids in the treatment of patients with liver cirrhosis. Vrach. Delo 4, 70–72 (1972).
Marquier, A.: L’oxymetholone en geriatric Experience sur quarantecinq cas. Rev. franç. Géront. 10, 294–296 (1964).
Martini, G.A., Strohmeyer, G., Dölle, W.: Was ist gesichert in der Therapie von Leberkran-ken? Internist 10, 456–464 (1969).
Martins, J.K.: Corticosteroid side effects counteracted by anabolic therapy. Gen. Pract. Kansas 27, 6–9 (1964).
Masson, G., Corcoran, A.C., Page, I.H.: Dietary and hormonal influences in experimental uremia. J. Lab. clin. Med. 34, 925–931 (1949).
Matsumoto, S., Takabatake, Y., Seike, S.: Clinical and experimental study on the effect of protein anabolic hormone, deca-durabolin, on lesions of bones and joints. Excerpta med. (Sect. 3) 17, 536 (1963).
Matzelt, D.: Beeinflussung von Serum-Enzymaktivitäten durch anabole Steroide bei muskel-kranken Patienten. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.
Meerson, F.S.: Hyperfunktion, Hypertrophic und Insuffizienz des Herzens. Berlin: VEB Verlag Volk und Gesundheit 1969.
Melmon, K.L., Morrelli, H.F.: Clinical Pharmacology. New York: MacMillan Company 1972.
Mendenhall, C.L.: Augmented release of hepatic triglycerides with anabolic steroids in patients with fatty liver. Amer. J. dig. Dis. 19, 122–126 (1974).
Menon, I.S.: Treatment of cutaneous vasculitis and recurrent superficial phlebitis and thromboembolism. Antiseptic 67, 776–780 (1970).
Menon, I.S.: Metformin and stanozolol in blood fibrinolytic activity. Brit. med. J. 1971I, 289–290.
Menon, I.S.: The role of phenformin and ethyloestrenol or stanozolol in the treatment of decreased fibrinolytic states. Acta Univ. Carol. (Med. Monogr.) 52, 19–23 (1972).
Menon, I.S., Cunliffe, W.J.: Phenformin and ethyloestrenol for Raynaud’s disease. Lancet 1969II, 1135.
Menon, I.S., Cunliffe, W.J., Dewar, H.A.: Preliminary report of beneficial effect of phenformin in combination with ethyloestrenol in treatment of cutaneous vasculitis and Behcet’s syndrome. Postgrad. med. J. (Suppl. May), 62–63 (1969).
Menon, I.S., Cunliffe, W.J., Weightman, D., Dewar, H.A.: Phenformin and stanozolol in blood fibrinolytic activity. Brit. med. J. 1970I, 428.
Merrill, J. P.: The Treatment of Renal Failure. New York: Grune & Stratton 1955.
Mertens, H.G.: Anabole Steroide bei Muskelkrankheiten. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.
Mezzena, R., Foresti, M., Trisotto, M., Bruni, G.: Studio di farmacologia umana sul quinbo-lone. G. Geront. 20, 361–378 (1972).
Michaelsson, G., Petterson, L., Juhlin, L.: Purpura caused by food and drug additives. Arch. Derm. 109, 49–52 (1974).
Milhorat, A.T.: Discussion on Dowben, R.M., Anabole Steroide bei Myopathien. Myopathien. Stuttgart: Georg Thieme Verlag 1965.
Miranda, G., Jimenez, G., Lara, F.: Estudio comparativo en hepatitis viral tratada con anabolicos. Acta méd. costaric. 13, 155–159 (1970).
Mitrofanov, V.S., Seliverstov, S.A., Markin, V.A.: Evaluation of the nerobol and prednisolone effectiveness in experimental myocardial infarction. Farmakol. i. Toksikol. 36, 316–319 (1973).
Moench, A., Sarre, H., Sartorius, H.: Klinische und experimentelle Untersuchungen zur Frage der Beeinflussung von Nierenläsionen durch Sexualhormone, fetale Nieren-Trockenzellen und Heparin. Verh. dtsch. Ges. inn. Med. 60, 527–534 (1954).
Moench, A., Sartorius, H.: Klinische Untersuchungen über Testosteronbehandlung beim ne-phrotischen Syndrom. Klin. Wschr. 32, 329–330 (1954).
Moench, A., Vogt, A.: Studien zur Frage der Hormonbehandlung bei experimenteller Nephritis-Nephrose der weißen Ratte. Verh. dtsch. Ges. inn. Med. 64, 527–531 (1958).
Moinade, S.: Action du trenbolone dans les dénutritions les cirrhoses et les ostéoporoses, étude a partir de 31 cas. Vie méd. 6, 605–608 (1974).
Molino, N., Belluardo, C., Rosso, B.: Le sindromi disprotidemiche in geriatria e loro trattamento con un nuovo steroide anabolizzante derivato dall’androstano (2-formil-11 alfa-idrossi-delta-metiltestosterone). Nostra esperienza clinica. Clin. Ter. 66, 167–198 (1973).
Molnar, G.D., Rosevaer, J.W., Gastineau, C.F., Moxness, K.E.: Effects of anabolic steroids on diabetic instability. Amer. J. med. Sci. 249, 280–290 (1965).
Moore, F.D., Ball, R.M.: The Metabolic Response to Surgery. Springfield: Ch. C. Thomas 1952.
Moore Ede, M.C., Burr, R.G.: Circadian rhythm of therapeutic effectiveness of oxymetholone in paraplegic patients. Clin. Pharmacol. Ther. 14, 448–454 (1973).
Morin, J.-P.: Contribution a Fetude des anabolisants dans le traitement de la tuberculose pulmonale. Thesis, Marseille 1960.
Morrison, B.O.: Use of analeptic, anti-depressant and anabolic drugs in treatment of the aged. J. Mich. St. med. Soc. 60, 723–726 (1961).
Müting, D.: Die Wirkung einer Langzeitbehandlung mit einer anabolen Substanz (Nandrolon-decanoat) auf Proteinsynthese und-abbau sowie Ausscheidungs-und Entgiftungsfunktion der Leber bei chronischen Leberkrankheiten und Diabetes mellitus. Klin. Wschr. 42, 843–848 (1964).
Muting, D.: Protein metabolism, excretion, and detoxication functions of the liver after long-term treatment of liver cirrhosis with an anabolic substance. Amer. J. dig. Dis. 10, 790–795 (1965).
Murakami, M., Odake, K., Matsuda, T. et al.: Effects of anabolic steroids on anticoagulant requirements. Jap. Circ. J. 29, 243 (1965).
Nanivadekar, S. A., Nanivadekar, A. S.: Gargoylism (Report of 3 cases and their treatment with nandrolone). J. J.J. Group Hosp. Grant med. Coll. 11, 176–181 (1966).
Nasso, S., Pedretti, G., Levorato, F.: Tentativo di profilassi della varicella con steroidi anabol-izzanti ed antirachitic!. Minerva pediat. 16, 390–394 (1964).
Navratil, J., Hrbek, J., Dvorak, M.: The therapeutic effect of stenolon spofa on female neurotic patients. Activ. nerv. sup. (Praha) 14, 102–103 (1972).
Nethercott, J., Lester, R.S.: Azathioprine therapy in incomplete Behçet syndrome. Arch. Derm. 110, 432–434 (1974).
Nikolaeva, L.F., Cherpachenko, N.M., Veselova, S.A., Sokolova, R.I.: Mechanisms of drug action on recovery processes of cardiac muscle in myocardial infarction. Circulation Res. 34/35, Suppl. III, 202–214 (1974).
Nilsson, I. M., Hedner, U., Isacson, S.: Phenformin and ethyloestrenol in recurrent venous thrombosis. Acta med. scand., 198, 107–113 (1975).
Nilsson, I.M., Isacson, S.: Thrombolytic therapy: long-term enhancement with oral agents. Effect of treatment with combined phenformin and ethyloestrenol on the coagulation and fibrinolytic systems. J. clin. Path. 25, 638–639 (1972).
Novak, E.: The effect of fluoxymesterone on plasma lipids in men. Int. med. Digest 6, 17–23 (1971).
Novak, E., Hendrix, J.W., Seckman, C.E., Penner, J.A.: A pharmacologic evaluation of fluoxy-mesterone in normal men. Curr. ther. Res. 16, 251–260 (1974).
Nowy, H., Frings, H.D., Frost, H.: Effekte von Anabolika auf den Herzmuskel. Arzneimittel-Forsch. 13, 716–717 (1963b).
Nowy, H., Frings, H.D., Seitz, W., Hashemi, I.: Effekte von Anabolika auf den Herzmuskel. Arzneimittel-Forsch. 13, 436–438 (1963a).
Nyfos, L.: Durabolinbehandling af muskeldystrofi. Ugeskr. Laeg. 124, 1412 (1962).
O’Grady, B.A.: The influence of drugs and diseases on the prothrombin time. Canad. J. med. Technol. 28, 140 (1966).
Ojala, L.: Experiences on deca durabolin treatment of diabetic retinopathy. Acta ophthal. (Kbh.) 42, 519–522 (1964).
O’Keefe, S.J.D., Sender, P.M., James, W.P.T.: Catabolic loss of body nitrogen in response to surgery. Lancet 1974II, 1035–1038.
Oldershausen, H.-F.v.: Verfolgung der Radiojodbengalrosaelimination bei Ratten nach einma-liger sowie langfristiger Verabreichung verschiedener anaboler Steroide. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964a.
Oldershausen, H.-F. v.: Verfolgung der Serumaktivitäten an Transaminasen und Aldolase bei Kaninchen und Hunden nach langfristiger Verabreichung von Methenolon. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964b.
Oldershausen, H.-F. v.: Zur Abhängigkeit funktioneller Veränderungen der Leber von der chemischen Struktur, Dosis und Applikationsweise anaboler Steroide bei lebergesunden Patienten und Kranken mit Leberzirrhose. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964c.
Oliveri, M.: La dimetazina quale terapia coadjuvante alla telecobalto-terapia in portatori di neoplasic polmonari. Gazz. med. ital. 126, 399 (1967).
Olson, R. E.: Metabolic interventions in the treatment of infarcting myocardium. Circulation 40, Suppl. 4, IV-195–IV-201 (1969).
Olsson, A.G., Orö, L., Rössner, S.: Effects of oxandrolone on plasma lipoproteins and the intravenous fat tolerance in man. Atherosclerosis 19, 337–346 (1974).
Oosterhuis, J. A.: Retinopathia diabetica. Thesis, Amsterdam 1960. OosterhuisJ.A.: Discussion to a lecture of L.E.M. Valk. Ned. T. Geneesk. 107, II, 1775 (1963).
Oosterhuis, J.A., Loewer-Sieger, D.H.: Behandeling van patienten met diabetische retinopa-thie met nandrolondecanoaat (Deca-durabolin). Ned. T. Geneesk. 106, II, 1574 (1962a).
Oosterhuis, J.A., Loewer-Sieger, D.H.: Treatment of diabetic retinopathy with nandrolone-decanoate (decadurabolin). Ophthalmologica 144, 346–370 (1962b).
Otter, G. den: The influence of anabolic substances on the nitrogen balance in surgical patients. Arch. chir. neerl. 12, 496–504 (1960).
Overbeek, G.A.: Anabole Steroide, Chemie und Pharmakologie. Berlin-Heidelberg-New York: Springer-Verlag 1966.
Oya, J.C. de, del Rio, A., Noya, M., Villanueva, A.: Decreased anticoagulant tolerance oxy-metholone in paroxysmal nocturnal haemoglobinuria. Lancet 1971II, 259.
Page, C. W.: The treatment of debility: a controlled experience. Paper presented at a Symposium on Anabolic Therapy, Detroit, Michigan, March 1962.
Panek, R.: Untersuchungen über den Mechanismus der strahlenschützenden Wirkungen der anabolen Steroide. Strahlentherapie 143, 211–218 (1972a).
Panek, R.: Untersuchungen über den Mechanismus der strahlenschützenden Wirkung der anabolen Steroide. Strahlentherapie 143, 444–453 (1972b).
Panek, R.: Untersuchungen über die Steigerung des strahlenschützenden Effekts der anabolen Steroide. Strahlentherapie 143, 559–569 (1972c).
Pani, A.: L’associazione steroidi anabolizzanti ed insulinaglucosio nella terapia degli stati ipera-zotemici. Clin. ter. 46, 303–314 (1968).
Panigada, G., Perletti, L., Magni, L., Giovannini, M.: Influenza di uno steroide anabolizzante sulla fenilalaninemia in lattanti distrofici. Minerva pediat. 20, 491–494 (1968).
Paolino, J.S., Kaplan, D., Lazarus, R., Emmanuel, G., Diamond, H.S.: Phenformin and ethyl-oestrenol in scleroderma. Lancet 1972I, 1023.
Parsons, F.M., McCracken, B.H.: The artificial kidney. Brit. med. J. 1959I, 740–751.
Pasqualicchio, A., Pasoli, C.A., Forte, P.L., Corbellari, G.C.: Contributo al trattamento delle sindromi carenziali nel vecchio. Minerva med. 63, 2425–2430 (1972).
Pateisky, K., Schinko, H., Haberler, H.: A study of the treatment of dystrophia musculorum progressiva with an anabolic steroid: nor-androstenolone decanoate. Acta endocr. (Kbh.) 63, 185–196 (1961).
Patnaik, D.N., Nath, R., Pathak, I.C.: The effect of methandienone (an anabolic steroid) on nitrogen metabolism following surgical trauma. Indian J. med. Res. 57, 1751–1760 (1969).
Payne, R.W.: Anabolism, appetite, and ambition. Kentucky Acad. gener. Pract. J. 5, 20–21 (1959).
Pearson, S., Weissberg, J., McGavack, T.H.: Steroid studies. I. Metabolic effects of androstano-lone in aged people. J. Amer. Geriat. Soc. 2, 26 (1954).
Pena, E. de la: Clinical use of oxymetholone in geriatrics. Sem. Méd. (Méx.) 27, 205–207 (1960).
Pentycross, C.R., Toussis, D., McKinna, J.A., Lawler, S.D., Greening, W.P.: Effect of hormone therapy on mitogenic responses of lymphocytes from patients with cancer of the breast. Lancet 1973II, 177–179.
Pergola, I.: Pren. méd. argent. 49, 274 (1962), cited by Tainter, M.L., Arnold, A., Beyler, A.L., Coulston, F., Potts, S.G.O., Roth, C.H.: A summary of the comparative therapeutic actions of stanozolol, an oral anabolic steroid. Clin. Med. 1964, 2089–2102.
Pestalozzi, D.: Zur Behandlung der Retinopathia diabetica mit Deca-Durabolin. Ophthalmologica 147, 125–133 (1964).
Petrochilos, A.M.: Steroides anabolisants sur la rétinopathie diabétique. Nosokom. Chron. 29, 201–203 (1967).
Petzold, H., Matzkowski, H., Burckhardt, M.: Der Einfluß von Oral-Turinabol auf die „Thioacetamidzirrhose” der Rattenleber. Dtsch. Z. Verdau.- u. Stoffwechselkr. 29, 3 (1969).
Pevchikh, V.V.: Anabolic steroids in the therapy of patients suffering from some diseases of the gastro-intestinal tract. Ter. Arkh. 41, 69–72 (1969).
Pezold, F.A.: Anabole Hormone bei chronischer Hepatitis. Orale Therapie mit 1α, 7α-Bis(ace-tylthio)-17α-methyltestosteron. Munch. med. Wschr. 110, 2663–2668 (1968).
Piatti, N., Pozzi, G.: Sperimentazione con 2-formil-17α-metilandrosta-l, 4-dien-11α, 17β-diol-3-one in clinica geriatrica. Clin. Ter. 74, 145–166 (1975).
Picha, E.: Anabole Steroide bei der Strahlentherapie weiblicher Genitalkarzinome. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.
Picha, E.: Neue Gesichtspunkte zur Anwendung anaboler Steroide in der gynäkologischen Strahlentherapie. Strahlentherapie 138, 300–322 (1969).
Pohle, H.: Verlaufsbeobachtungen einzelner Leberfunktionsprüfungen unter oraler Applikation von Methenolon und 1-Phenylpropanol bei Lebergesunden. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.
Polischuk, M.A.: The clinical assessment of the use of strophanthin and nerobol in cardiac insufficiency. Klin. Med. (Moskau) 48, 53–56 (1970).
Porsio, A.: Controlled clinical trials of a new anabolic agent in chronic TB patients. Clin. ter. 37, 502–518 (1966).
Porsio, A.: Ricerche cliniche controllate su due anabolizzanti ad azione protratta. Minerva med. 59, 824–828 (1968).
Porter, R., Knight, J. (ed.): Energy metabolism in trauma. A Ciba Foundation Symposium. London: J. & A. Churchill 1970. Porto, A. L.: O tratamento testosterónico da cirrose hepática. Thésis, Coimbra 1968.
Poser, G., Kluthe, R., Adler, P.: Zur Therapie des nephrotischen Syndroms. Med. Klin. 61, 432–435 (1966).
Pozzetto, M.H.: Un anabolisant, le phenylpropionate de nandrolone, en pneumophtisiologie. Rev. Lyon Med. 10, 961–968 (1961).
Prikhozan, V.M.: Pathogenesis of the nervous system affection in diabetes mellitus. Probl. Endokrinol. Gormonterap. 14, 14–18 (1968).
Probst, J.-H.: Treatment of children suffering from disorders of muscular movement with dura-bolin and decadurabolin. Proc. VII. Intern. Congr. Neurology 2, 645–652 (1961).
Pruss, G.M., Markovskaia, G.I., Bosko, A.P.: In: Profilaktika i lechenie koronarnoi i serdechnoi nedostatochnosti. Leningrad 1967.
Quack, G.: Primobolan als Zusatztherapie bei der Strahlenbehandlung. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.
Quack, G., Gaebel, E.: Primobolan-Depot in der Strahlentherapie. Med. Mitt. Schering 23, 16 (1962)
Rabier, M.: Utilisation d’un anabolisant dans la tuberculose pulmonaire du noir africain. Afr. méd. 95 (1971).
Rabinowitz, J.L., Chase, G.D., Myerson, R.M.: Failure of anabolic steroid, oxymetholone, to influence survival time of dystrophic mice. Amer. J. med. Sci. 246, 456–458 (1963).
Ravens, K.G.: Der Einfluß von anabolen Hormonen und von Diät auf den myokardialen Gehalt an energiereichen Phosphaten während der Infarktheilung. Verh. dtsch. Ges. Kreisl.-Forsch. 36, 314–319, 389 (1970).
Rebora Togno, F.: El decanoato de nandrolona como coadyuvante del medico o quirurgico de la tuberculosis pulmonar. Sem. Méd. (Méx.) 67, 146–150 (1971).
Rehn, J., Spinner, M.-E.: Die Anwendung anabol wirksamer Hormone in der Chirurgie. Med. Welt (Stuttg.) 25, 1401–1405 (1962).
Reiss, M., Hillman, J.C., Reiss, J., Daley, N., Haylock, S.: Influence of anabolic hormones on phenylalanine metabolism. I. Studies on chronic phenylketonuric patients. J. ment. Defic. Res. 10, 20 (1966b).
Reiss, M., Sideman, M.B., Plichta, E.S.: Influence of anabolic hormones on phenylalanine metabolism. II. Studies in animals. J. ment. Defic. Res. 10, 130–140 (1966a).
Ren, G. de, Meyer, D., Simon, G.: Utilisation du phenyl-propionate de nor-androstenolone en phtisiologie. Vie méd. 42, 739–751 (1961).
Resan, T.K., Shahidi, N.T., Korst, D.R.: Effect of phenobarbital on testosterone-induced ery-thropoiesis. J. Lab. clin. Med. 79, 187 (1972).
Rigberg, S.V., BrodskyJ.: Potential roles of androgens and the anabolic steroids in the treatment of cancer. A review. J. Med. 6, 271–290 (1975).
Riordan, D. J., Browne, P.A.: The treatment of secondary deposits in bone from carcinoma of the breast with radio-active phosphorus and durabolin. J. Irish med. Ass. 99, 40–44 (1961).
Roberts, H.J.: Radiotherapy in herpes zoster. Lancet 1965II, 1074.
Roberts, H.J.: Timed repetitive ankle jerk (TRAJ) responses in ‘early’ diabetic neuropathy: Diagnostic and therapeutic observations, with particular reference to the effects of nandro-lone. Diabetes 18, 370–371 (1969).
Roberts, P.S., Burkat, R.K.: Effects of biguanides on reactions of thrombin and on 1-stage prothrombin time of standard human plasma. Ann. N.Y. Acad. Sci. 714 (1968).
Robinson, B.H.B., Hawkins, J.B., Ellis, J.E.: Decreased anticoagulant tolerance with oxymetholone. Lancet 1971I, 1356.
Robinson, R.W., LeBeau, R.J.: Effect of oxandrolone on hyperlipemia. Circulation 42, Suppl. 3, 55 (1970).
Robson, A.M., Ashcroft, R., Clarkson, B.A., Horn, D.B., Kerr, D.N.S.: The effect of an anabolic steroid (Deca-Durabolin) on urea production. Proc. europ. Dialys. Transpl. Ass. (EDTAProc.) 1, 159 (1964a).
Robson, A.M., Ashcroft, R., Clarkson, B.A., Horn, D.B., Kerr, D.N.S.: Diet and anabolic steroids. In: Sheldon, S., Cook, S. (Eds.): Acute Renal Failure. Oxford: Blackwell 1964b.
Robson, A.M., Ashcroft, R., Clarkson, B.A., Horn, D.B., Kerr, D.N.S.: Urea metabolism in chronic uremia: Effect of protein restriction, anabolic steroids and antibiotics. In: Berlyne, G.M. (Ed.): Nutrition in Renal Disease. Edinburgh: Livingstone 1968.
Rohwedder, H.J.: Beobachtungen bei der Anwendung anaboler Steroide bei Kindern mit ne-phrotischem Syndrom. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.
Rosnick, M.J.: Use of anabolic steroid, stanozolol, to promote weight gain in underweight patients. Clin. Med. 71, 989 (1964).
Rouher, F., Serpin, G.: Action du phenyl-propionate de nor-androstenolone dans la retinopa-thie diabétique. Presse méd. 72, 2211–2212 (1964).
Roy, J. A.: Study of the correction of protein disorders seen in the course of alcoholic cirrhosis by androstanolone. Thesis, Bordeaux 1961.
Rozman, C., Urbano, A., Galera, H.: Lebertoxizität der anabolen Steroide. Münch. med. Wschr. 113, 965–967 (1971).
Ruprecht, K. W.: Diabetische Retinopathie. Med. Welt 26, 1822–1825 (1975).
Sachs, B.A., Wolfman, L.: Effect of oxandrolone on plasma lipids and lipoproteins of patients with disorders of lipid metabolism. Metabolism 17, 400–410 (1968).
Saito, T., Saito, M.: Studies on the action mechanism of anabolic steroids. II. The effect on the serum glycoproteins. Iryo 20, 1154–1161 (1966).
Saito, T., Shirata, S., Nakamura, R., Saito, M.: Studies on the action mechanisms of anabolic steroids. I. Clinico-pharmacological studies on their effects upon the far advanced pulmonary tuberculous patients. Iryo 20, 565–572 (1966).
Sansoy, P. M., Naylor Roy, A., Shields, L. M.: Anabolic action and side effect of oxandrolone in 34 mental patients. Geriatrics 26, 139–143 (1971).
Santalo, M., Echevarne, F.: Untersuchungen des Mongolismus und seine Behandlung mit Norandrostenolonphenylpropionat. Med. Welt 34, 1683–1686 (1963).
Sarre, H.: Die Therapie des akuten Nierenversagens. Mkurse ärztl. Fortbild. 13, 298 (1963).
Sarre, H.: Einführung zu „Anabolika bei Nierenerkrankungen”. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.
Sarre, H.: Diuresetherapie. Med. Klin. 61, 2009–2013 (1966).
Saskin, E., Waldman, S., Pelner, L.: Diabetic retinopathy; a new approach to therapy with a steroid hormone testosterone propionate. Amer. J. Ophthal. 3, 613 (1951).
Schilling, A., Finkel, H.E.: Ancillary measures in treatment of myeloma. Use of immune serum globulin, fluoride, or androgen. Arch. intern. Med. 135, 193–196 (1975).
Schimmelpfennig, W.: Anabole Steroide und Nierenerkrankungen. Dtsch. Gesundh.-Wes. 21, 97–100 (1965).
Schindler, H.: Marfan-Syndrom mit Morbus Addison und Akromegalie. Wien. med. Wschr. 125, 643–644 (1975).
Schindler, H., Korn, A.: Anabole Steroide und ihre hormonellen Nebenwirkungen. Munch. med. Wschr. 107, 479 (1965).
Schnack, H.: Tierexperimentelle Untersuchungen mit anabolen Steroiden. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964a.
Schnack, H.: Klinische Untersuchungen mit Steroiden der Primobolan-Reihe im Kurzversuch. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964b.
Schnack, H.: Klinische Erfahrungen über Langzeitbehandlung von Leberzirrhosen mit anabolen Steroiden der Primobolan-Reihe. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964c.
Schnack, H., Schobel, B., Wewalka, F.: Therapie der Leberzirrhose mit anabolen Steroiden. Wien. klin. Wschr. 74, 833–836 (1962).
Schoppe, W.-D.: Die Beeinflussung des Eiweißstoffwechsels lungenoperierter Patienten durch anabole Steroide bei postoperativer Zufuhr von kliniksüblicher Kost. Dissertation, Düssel-dorf 1971.
Schrogie, J.J., Solomon, H.M.: Hazards of multiple drug therapy in patients taking coumarin anticoagulants. Circulation 34, Suppl. III-210–III-211 (1966).
Schrogie, J.J., Solomon, H.M.: The anticoagulant response to bishydroxycoumarin. II. The effect of D-thyroxine, clofibrate, and norethandrolone. Clin. Pharmacol. Ther. 8, 70–77 (1967).
Schumacher, H.: Klinik und Pathophysiologic der diabetischen Retinopathie. Med. Welt (Berl.) 18, 96–100 (1967).
Schwarz, F.K.T.: Revitalisierung beim alternden Menschen durch eine multivalente Vitamin-Mineral-Anabolikum-Kombination. Hippokrates 38, 900–902 (1967).
Schwarz, W., Kutzsche, A.: Elektronenmikroskopische Untersuchungen über die anabole und katabole Wirkung von Dexamethason und Methenolonester auf Fibroblasten in vitro. Klin. Wschr. 44, 979–982 (1966).
Scuderi, G., Sborgia, G.: Terapia della retinopatia diabetica. Clin. Ter. 70, Suppl. 3, 42–61 (1974).
Segers, J., Nuyts, J.A.: Clinical trial with oxymetholone in a group of schizophrenic patients. Acta neurol. belg. 64, 736–745 (1964).
Seifert, E.: Methenolonazetat und-önanthat bei chronischer Hepatitis und Leberzirrhose. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.
Selye, H.: On the protective action of testosterone against the kidney damaging effect of sublimate. J. Pharmacol. exp. Ther. 68, 454–457 (1940).
Selye, H.: Catatoxic steroids. Canad. med. Ass. J. 101, 51–52 (1969).
Selye, H.: Prevention of colchicine intoxication by catatoxic steroids. Endocrinologia Exp. 4, 71–76 (1970a).
Selye, H.: Resistance to picrotoxin poisoning induced by catatoxic steroids. Agents and Actions 1, 133–135 (1970b).
Selye, H.: Resistance to various pesticides induced by catatoxic steroids. J. Amer. med. Ass. 214, 2072 (1970c).
Selye, H.: Hormone und Widerstandsfähigkeit. Münch. med. Wschr. 112, 1401–1407 (1970d).
Selye, H.: Protection by catatoxic steroids against cycloheximide intoxication. Toxical appl. Pharmacol. 17, 721–725 (1970e).
Selye, H.: Conditioning of catatoxic steroid actions by the thyroid. J. Med. 1, 43–55 (1970f).
Selye, H.: Protection against LSD by various steroids. Life Sci. 10, 1135–1140 (1971).
Selye, H.: Hormones and resistance. Berlin-Heidelberg-New York: Springer-Verlag 1971.
Selye, H., Jelinek, J., Krajny, M.: Prevention of digitoxin poisoning by various steroids. J. Pharm. Sci. 58, 1055–1059 (1969).
Selye, H., Solymoss, B.: Protection by catatoxic steroids against meprobamate. Neuropharmacology 9, 327–332 (1970).
Selye, H., Yeghiayan, E., Mandeville, R.: Protection by catatoxic steroids against dihydro-tachysterol intoxication. Atherosclerosis 11, 321–331 (1970).
Selye, H., Yeghiayan, E., Mecs, I.: Prevention of nicotine intoxication by catatoxic steroids. Arch. int. Pharmacodyn. 183, 235–238 (1970).
Seneca, H.: Endotoxic shock and hyperpyrexia in urological practice. J. Amer. Geriat. Soc. 16, 733–744 (1968).
Seneca, H., Peer, P.: Effect of estrogens and anabolic steroids on renal infections in normal and immunized/sensitized rats and mice. Bact. Proc. 99 (1967a).
Seneca, H., Peer, P.: Effect of estrogens and anabolic steroids on experimental infections. International Congress of Chemotherapy, Vienna 1967b.
Sereni, F., Piceni-Sereni, L., De Ritis, L.: Influence of an anabolising steroid on the metabolic balance of nitrogen in the nephrotic syndrome. Minerva pediat. 11, 1124–1128 (1959).
Settel, E.: Protein metabolism in the elderly: A cross-over study of a hormonal anabolic agent (methandrostenolone) and a non-hormonal agent (enzyme-vitamin complex). J. Amer. Geriat. Soc. 12, 538–547 (1964).
Sevin, R., Cuendet, J.F.: La rétinopathie diabétique. Son traitement médical. Praxis 60, 612–614(1971).
Shahidi, N.T.: Barbiturate effect in androgen therapy. New Engl. J. Med. 287, 309 (1972).
Sharma, K.K., Misra, M.B., Dixit, B.B., Sastri, P.S.R.: Effect of ethyloestrenol on serum cholesterol in rabbits. Indian Drugs Annual 17–19 (July 1975).
Shils, M.E.: Renal disease and metabolic effects of tetracycline. Ann. intern. Med. 58, 389 (1963).
Siegmund, G.: Die Anwendung eines anabolen Steroids bei Erkrankungen des rheumatischen Formenkreises. Med. Klin. 58, 995–998 (1963).
Sigler, H., Issekutz, B.: Effects of anabolic steroids in chronic renal failure. Arch. intern. Med. 120, 408–416 (1967).
Silk, R.E.: Management of protein and fat losses in surgical patients. J. Albert Einstein med. Center 10, 181–187 (1962).
Sim, A.W., Henderson, P.S., Vies, J., van der: The effect of steroids on the biosynthesis of collagen in rat skin. Paper presented at III. European Symposium on Connective Tissue Research, Turku, August 1972.
Sim, A.W., Picton, W., Fox, P.K., Walker, G.B.: The effect of topical corticosteroids on the metabolism of dermal collagen. In: Proceedings of Glaxo Symposium on Mechanism of Action of Corticosteroids, Edinburgh-London: Livingstone 1975.
Sinitzin, P.D., Agafonowa, G.A.: Clinical evaluation of the effect of anabolic preparations on the effectiveness of treatment in peptic ulcer. Sovetsk. Med. 150–151 (1975).
Skikantia, S.G., JayaRao, K.S., Prasad, P.S.: Effect of a C-17 alkylated steroid, methylandro-stenolone, on plasma lipids of normal subjects. Amer. J. med. Sci. 254, 201 (1967).
Smith, C., Johnson, P.C.: Anabolic effect of 19-nortestosterone phenylpropionate in underweight geriatric women. J. Amer. Geriat. Soc. 9, 304–311 (1961).
Snow, E.W.: Stanozolol, a new anabolic agent: Clinical observations in seventy-two patients. Med. Tms 91, 149–157 (1963).
Snyder, D., Brest, A. B.: Chronic renal insufficiency treated with anabolic steroid. Effect on acid-base balance, protein metabolism and hematopoiesis. J. Amer. Geriat. Soc. 14, 21 (1966).
Soecknick, H.: Fertabolin in der Geriatric Prakt. Arzt 299, 509–526 (1972).
Sokolova, T.S., Fedotova, A.M., Balashova, U.A.: The complex employment of anabolic hormones and antihistamine preparations in treating allergic diseases in early childhood. Pediatriia (Moskwa) 44, 34–39 (1965).
Soler-Argilaga, C.: Esteroides anabolizantes. II. algunos aspectos de nuestra experiencia clinica sobre esteroides anabolizantes. An. Med. (Med.) 50, 203–219 (1964).
Sons, W. A.: Stanozolol in urological surgery. Dia Medico 43, 1669–1670 (1971).
Solymoss, B., Toth, S., Varga, S., Selye, H.: Protection by spironolactone and oxandrolone against chronic digitoxin or indomethacin intoxication. Toxical appl. Pharmacol. 18, 586–592 (1971).
Spencer, D.A.: Letter to the editor. Med. News, No. 228, 12 (1967).
Stenzel, K.H., Cheigh, J.S., Sullivan, J.F., Tapia, L., Ruggio, R.R., Rubin, A.L.: Clinical effects of bilateral nephrectomy. Amer. J. Med. 58, 1, 69–75 (1975).
Stepan, J., Bremova, A.: Stromba bei Erkrankungen des Bewegungsapparates. Med. Klin. 62, 1470–1474 (1967).
Stöckl, W., Geyrhofer, K.: Die Beeinflussung der Antikörperbildung durch Sanabolicum. Wien. tierärztl. Mschr. 52, 94–98 (1965).
Stone, M.C.: Idiopathic hyperglyceridemia treated with methyltestosterone and methandienone. Lancet 1963I, 477.
Stone, M.C.: Elevation of serum-cholesterol by an anabolic steroid. Lancet 1964I, 474.
Stuhlfauth, K., Frost, H.: Medikamentöse Rehabilitation und Behandlung der Hypotonie mit Steroidhormonen. Munch. med. Wschr. 106, 498–502 (1964).
Stur, O.: Durabolinbehandlung bei infantiler spinaler Muskelatrophie. Wien. klin. Wschr. 72, 54–55 (1960).
Svendsen, B.B.: Negative results of treatment with nortestosterone in urinary incontinency in women with senile dementia. Nord. Med. 62, 1516–1517 (1959).
Szold, E.: Die Wirkung von Methylandrostendiol und Norandrostenolon in experimenteller Uramie. (Hungarian). Magy. Sebész. 12, 368–369 (1959).
Szold, E., Szendroi, Z., Weisz, P., Pinter, I., Desi, I., Kadas, T.: Anabolic steroids in uremia. Lancet 1959II, 368–369.
Tache, Y., Tache, J., Selye, H.: Inhibition of the effects of Alfathesin and other steroid anesthetics by catatoxic steroids in rats. Arzneimittel-Forsch. 25, 1603–1606 (1975).
Tainter, M.L.: Anabolic steroids in the management of the diabetic patient. N.Y. St. J. Med. 64, 1001–1009 (1962).
Tamburro, C., Leevy, C.M.: Protein clotting factor synthesis in liver disease. Gastroenterology 52, 325 (1967).
Tan, R.S.H., Copeman, P. W.M.: Blood hypercoagulability causing leg ulcerations. Brit. J. Derm. 91, 46–48 (1974).
Tec, L.: Durabolin in anorexia nervosa. Amer. J. Psychiat. 120, 282 (1963).
Tec, L.: Anorexia nervosa—follow-up on a special method of treatment. Amer. J. Psychiat. 127, 1702 (1971).
Tec, L.: Nandrolone in anorexia nervosa. J. Amer. med. Ass. 229, 1423 (1974).
Thaysen, J.H.: Protein metabolism. Internat. Symposion, Leyden. Berlin-Göttingen-Heidelberg: Springer 1962.
Tichy, A., Dolecek, R., Klabusay, L.: Experimental cardiopathy in burned rats. Rozhl. Chir. 42, 230–236 (1963).
Tirkina, T.N., Aleksandriva, L.M., Klyachko, V.R., Mazovetsky, A.G.: Pyridinolcarbamate (anginin) in the treatment of diabetic angiopathy. Ter. Arkh. 46, 107–110 (1974).
Tolentino, P.: Protein anabolic steroid hormones and antibody formation. Ann. paediat. 199, 467–471 (1962).
Tolentino, P.: Gli steroidi anabolizzanti nella terapia delle epatiti virali. Epatologia 12, 461–469 (1966).
Tolentino, P.: Anabolische Steroide und Immunität. Münch. med. Wschr. 113, 953–955 (1971).
Tolentino, P., Terragna, A., Jannuzzi, C.: Ormoni steroidei ed anticorpopoiesi. Mancata azione di stimolo da parte di steroidi proteino-anabolici nella somministrazione distanziata dall’antigene o nella risposta anamnestica. Ann. Sclavo 6, 439–444 (1964).
Toni, E. de: Gli effetti degli steroidi anabolizzanti sul ricambio creatinico nella miodistrofia progressiva. Clin. pediat. 41, 441–445 (1959).
Toni, E. de: Treatment of progressive muscular dystrophy in particular with the anabolic steroids. Acta endocr. (Kbh.) 63, 175–184 (1961).
Toni, G. de: Sulla possibilitá di limitare o addirittura inibire la creatinuria patologica della miodistrofia progressiva mediante l’uso di forti dosi di steroide anabolizzanti. Boll Soc. ital. Biol. sper. 35, 110–114 (1959).
Trocme, P., Roy, J.: Essai de correction par l’androstanolone des troubles du métabolisme des protides chez les cirrhotiques. Sem. Hôp. Paris 38, 22–25 (1962).
Trusov, V.V., Vakhrushev, Y.M.: Evaluation of the therapeutic effect of the anabolic steroid agent androstanasol in patients with chronic gastritis. Vrach. Delo 8, 39–42 (1973).
Trusov, V.V., Vakhrushev, Y.M., Oreshkov, T.M.: Clinical evaluation of the therapeutic action of a new soviet-made preparation—androstanasol in patients with peptic ulcer. Ter. Arkh. 46, 96–100 (1974).
Turner, R.L.: Combined androgenic and cytotoxic therapy in carcinoma of the breast. Paper read at a Symposium at the University Dept. of Surgery, Royal Infirmary, Sheffield, Nov. 1966.
Tweedle, D.E.F., Walton, C., Johnston, I.D.A.: The effect of a long-acting anabolic steroid on nitrogen balance during the anabolic phase of recovery from abdominal surgery. Brit. J. Surg. 59, 300 (1972).
Tweedle, D.E.F., Walton, C., Johnston, I.D.A.: The effect of an anabolic steroid on postoperative nitrogen balance. Brit. J. clin. Pract. 27, 130–132 (1973).
Udupa, K.B., Reissmann, K.R.: Stimulation of granulopoiesis by androgens without concomitant increase in colony-stimulating factor. Clin. Res. 22, 609 A (1974).
Vadasz, I.: Effect of nandrolone decanoate on some forms of pulmonary tuberculosis. Arzneimit-tel-Forsch. 19, 100–103 (1969).
Vaisrub, S.: Intravascular factors in diabetic retinopathy. Editorial, J. amer. med. Ass. 233, 1303 (1975).
Vakhrushev, Y.M.: The experience of the therapeutic use of anabolic steroid of nerobol in combination with quateron in exacerbation of peptic ulcer. Terap. Arkh. 43, 26–30 (1971).
Vakhrushev, Y.M., Trusov, V.V.: Comparative characteristics of therapeutic efficacy of a number of medicinal combinations of patients with peptic ulcer. Terapevt. Arkh. 47, 108–113 (1975).
Valk, L. E.M.: Influence favorable du phénylpropionate de 19-nor-androsténolone sur rétinopa-thie diabétique. Bull. Soc. franc. Ophtal. 72, 596–608 (1959).
Valk, L.E.M.: Successen en tegenslagen bij de behandeling van diabetische retinopathie met anabole steroiden gedurende de laatste vijf jaren. Ned. T. Geneesk. 107, II, 1773–1776 (1963).
Valk, L.E.M.: Nandrolone decanoate, a useful anabolic steroid in diabetic retinopathy instead of destruction of the hypophysis. Excerpta med. Intern. Congr. Ser. 74, 36 (1964).
Valk, L.E.M., Vergroesen, J.A.J.: Een gunstige invloed van nandrolon decanoaat op oog en nier in enige gevallen van de ziekte van Kimmelstiel-Wilson; enige moeilijkheid bij de beoordeling van het nierbiopt. Ned. T. Geneesk. 113, 99 (1969).
Vasiukova, E.A., Margolis, M.G.: Complex treatment of patients with diabetes mellitus with diabetic retinopathy. Klin. Med. (Moskau) 53, 78–82 (1975).
Vasiukova, E.A., Zefirova, F.S., Briskin, A.L: Anabolic steroids in the treatment of endocrine disease. Ter. Arkh. 41, 9–15 (1969).
Vassella, F., Rossi, E., Aebi, U., Richterich, R.: Anabole Steroide bei progressiver Muskeldy-strophie. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.
Vere, D.W., Fearnley, G.R.: Suspected interaction between phenindione and ethyloestrenol. Lancet 1968II, 281.
Verevkin, A.M., Pevchikh, V.V.: Changes in gastric and hepatic function in peptic ulcer during treatment with an anabolic steroid preparation—nerobol. Ter. Arkh. 44, 36–39 (1972).
Vermeulen, A.: Influence of anabolic steroids on secretion and metabolism of Cortisol. In: Structure and metabolism of corticosteroids. London-New York: Academic Press 1964.
Vermeulen, A., Demeulenaere, L.: Einfluß anaboler Steroide auf Leberenzyme. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.
Vermeulen, H. J.: 17β-hydroxy-4-estren-3-one laurate, a new long-acting anabolic steroid. Arz-neimittel-Forsch. 18, 1458–1460 (1968).
Verstraete, M.: The position of long-term stimulation of the endogenous fibrinolytic system: Present achievements and clinical perspectives. Thrombos. Diathes. haemorrh. 34, 613–622 (1975).
Verwilghen, R., Louwagie, A., Waes, J., Vandenbroucke, J.: Anabolic agents and relative po-lycythaemia. Brit. J. Haemat. 12, 712–716 (1966).
Viallier, J.: Action de l’androstanolone base chez les tuberculeux pulmonaires. Lyon méd. 90, 32 (1958).
Vilanova, J.: The use of methandrostenolone (Dianabol) in improving nutrition in geriatric patients. J. med. Soc. N. Jersey 59, 65–68 (1962).
Vlavianos, G., Seaman, G., Vlavianos, M.: A further clinical study of anabolic steroids in incontinence. Amer. J. Psychiat. 118, 539–542 (1961).
Voss, H.E.: Androgene und Nieren. In: Voss, H.E., Oertel, G.: Androgene I, pp.551–556. Berlin-Heidelberg-New York: Springer-Verlag 1973 a.
Voss, H.E.: Androgene und Muskulatur. In: Voss, H.E., Oertel, G.: Androgene I, pp.559–566. Berlin-Heidelberg-New York: Springer-Verlag 1973b.
Voss, H.E.: Wirkung der Androgene auf die Wundheilung: In: Voss, H.E., Oertel, G.: Androgene I, pp.576–577. Berlin-Heidelberg-New York: Springer-Verlag 1973c.
Voss, H.E.: Die anti-hypercholesterinämische Wirkung der Androgene. In: Voss, H.E., Oer-tel, G.: Androgene I, pp.604–606. Berlin-Heidelberg-New York: Springer-Verlag 1973d.
Walker, I.D., Davidson, J.F., Young, P., Conkie, J.A.: Plasma fibrinolytic activity following oral anabolic steroid therapy. Thrombos. Diathes. haemorrh. 34, 236–245 (1975 a).
Walker, I.D., Davidson, J.F., Young, P., Conkie, J.A.: Effect of anabolic steroids on plasma antithrombin III, α 2-macroglobulin and α 1-antitrypsin levels. Thrombos. Diathes. haemorrh. 34, 106–114 (1975b).
Walsh, F.M., Harris, L.D., Schipke, J.M.: The treatment of diabetic vitreous hemorrhages. Minerva Med. 46, 641–644 (1963).
Wardle, E.N.: Study of the lipid-lowering action of choloxin and nilevar in patients with chronic renal failure. Postgrad. med. J. 50, 737–740 (1974).
Watkin, D.M., Parsons, J.M., Yiengst, M.J., Shock, N.W.: Metabolism in the aged: the effect of stanolone on the retention of nitrogen, potassium, phosphorus, and calcium and on the urinary excretion of 17-keto, 11-oxy, and 17-hydroxy steroids in eight elderly men on high and low protein diets. J. Gerontol. 10, 268–287 (1955).
Watschinger, B.: Verlaufsbeobachtungen bei Nephrosekranken. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.
Watts, G.T., Baddeley, M.R., Wellings, R., Evans, J.: The nature of wound healing: Experimental tensile strength studies with deca durabolin and S35. Ann. Surg. 162, 109–112 (1965).
Watzman, N., Kinnard, W.J., Aceto, M.D., Buckley, J.P.: Effects of certain compounds on experimental muscular dystrophy. J. pharm. Sci. 51, 1090–1095 (1962).
Weber, H., Hagge, W.: Über die erfolgreiche Behandlung der Zystinose mit einem Anabolicum. Arch. Kinderheilk. 168, 2 (1963).
Weiner, M., Siddiqui, A.A., Bostanci, N., Dayton, P.G.: Drug interactions: The effect of combined administration on the half-life of coumarin and pyrazolone drugs in man. Fed. Proc. 24, 153 (1965).
Weiner, M., Siddiqui, A.A., Shahani, R.T., Dayton, P.G.: Effect of steroids on disposition of oxyphenbutazone in man. Proc. Soc. exp. Biol. Med. 124, 1170–1173 (1967).
Weissel, W.: Anaboles Hormon bei malignem oder kompliziertem Diabetes mellitus. Wien. klin. Wschr. 74, 234–236 (1962).
Weller, O.: Die Wirkung von Methenolon auf die gesunde Leber. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964a.
Weller, O.: Die Verwendung von Methenolon bei akuten und chronischen Leberparenchym-Erkrankungen. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964b.
Weller, O., Voegt, H.: Therapie der Leberzirrhose. Therapiewoche 12, 665–668 (1962).
Wells, R.: Prednisolone and testosterone propionate in cirrhosis of the liver. A controlled trial. Lancet 1960II, 1416–1419.
Wenzel, B., Bünte, H.: Die Verwertung parenteral zugeführter Aminosäuren nach chirurgischen Operationen. Med. Ernähr. 9 (1968).
Werner, S.C.: Clinical syndromes associated with gonadal failure in men. Amer. J. Med. 3, 52–66 (1947).
Wernze, H.: Aufnahme und Ausscheidung von Bromsulfophthalein unter dem Einfluß anaboler Hormone durch die Leberzelle der Ratte. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964a.
Wernze, H.: Die Leberfunktion unter dem Einfluß verschiedener Testosteronabkömmlinge (Un-tersuchungen von Serum-Fermenten und Bromsulfophthalein-Ausscheidung). In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964b.
West, H.F., Lewis-Faning, E.: Controlled trial of methenolone acetate in prednisolone-treated rheumatoid arthritic patients. Ann. rheum. Dis. 24, 576–580 (1965).
Wewalka, F.: Anabolika bei chronischen Leberkrankheiten. Z. Gastroenterologie 1, 40–46 (1963).
Wewalka, F.: Anabole Steroide und Leberkrankheiten. Wien. med. Wschr. 117, 293–299 (1967).
Wewalka, F.: Die Behandlung der chronischen Leberkrankheiten mit anabolen Steroiden. Therapiewoche 18, 766–770 (1968).
Whyte, H.M.: Potential effect on coronary-heart-disease morbidity of lowering the blood-cholesterol. Lancet 1975I, 906–910.
Wiggins, R.A.: Observations of the use of 19-nortestosterone in patients with oliguric uremia. Sth. med. J. 56, 669–672 (1963).
Wildhirt, E.: Uber die Lebervertraglichkeit von Anabolika. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.
Wiles, F.J., Mackintosh, J.: Effect of durabolin in tuberculosis patients. Med. Proc. 8, 56–57 (1962).
Wilk, F., Rausch-Schott, G.: Die Zystinose. Wien. med. Wschr. 121, 349–353 (1971).
Williams, J.S., Stein, J.H., Ferris, T.F.: Nandrolone decanoate therapy for patients receiving hemodialysis. A controlled study. Arch, intern. Med. 134, 289–292 (1974).
Winther, C.: Testosterone and fibrinolytic activity. Scand. J. clin. Lab. Invest. 99, 207–210 (1967).
Winther, O.: Resistance to testosterone as a stimulation of blood fibrinolytic activity in patients with cancer of the breast. Lancet 1970I, 625.
Wolf, H.: Zur Behandlung der Untergewichtigkeit mit einem oral wirksamen Anabolikum. Wien. med. Wschr. 112, 382–384 (1962).
Wolpert, A., Sheppard, C., Merlis, S.: Method for evaluation of behavioural changes in aged hospital patients during anabolic steroid therapy. J. amer. Geriat. Soc. 15, 470–474 (1967).
Wolpert, A., Sheppard, C., Merlis, S.: Body weight as an index of therapeutic effect in anabolic steroid therapy. J. amer. Geriat. Soc. 16, 323–327 (1968).
Wolthuis, F.H.: Balance studies on protein metabolism; significance for the treatment of renal failure. Voeding 24, 372–386 (1963).
Worm, J.: Progressiv muskeldystrofi behandlet met durabolin. Ugeskr. Laeg. 124, 1325–1327 (1962).
Yamase, F., Hatanaka, H.: Effect of anabolic steroid for treatment of pulmonary tuberculosis. Med. J. Mut. Aid Ass. 12, 4 (1963).
Yoshida, H.: Clinical studies on the decholesterolizing effect of anadrol. Saishin Igaku 20, 2991–2997 (1965).
Zeneroli, M. L.: Sulle variazione della colesterolemia durante trattamenti prolungati con metan-drostenolone, ossimesterone e nandrolone. Endocr. Sci. Const. 31, 107–114 (1970).
Zorrilla, E., Magos, C., Serrano, P. A.: Efecto de la oxandrolona sobre los lipidos sericos en las hiperlipidemias primarias tipo IV y II b . Arch. Inst. Cardiol. Méx. 43, 270–278 (1973).
Zwozukiak, W., Zgorzalewicz, B.: Early and distant results of the treatment with the anabolic steroids of the progressive muscular dystrophy. Neurol. Neurochir. pol. 1, 345–351 (1967).
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1976 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Kopera, H. (1976). Miscellaneous Uses of Anabolic Steroids. In: Kochakian, C.D. (eds) Anabolic-Androgenic Steroids. Handbuch der experimentellen Pharmakologie / Handbook of Experimental Pharmacology, vol 43. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-66353-6_18
Download citation
DOI: https://doi.org/10.1007/978-3-642-66353-6_18
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-66355-0
Online ISBN: 978-3-642-66353-6
eBook Packages: Springer Book Archive